activates | 141,614 |
associated_with | 104,714 |
regulates | 76,158 |
inhibits | 58,840 |
interacts_with | 51,410 |
expressed_in | 44,697 |
therapeutic_target | 43,270 |
causes | 35,761 |
co_discussed | 24,690 |
biomarker_for | 14,446 |
protects_against | 12,040 |
data_in | 10,791 |
modulates | 10,344 |
treats | 9,421 |
participates_in | 8,684 |
contributes_to | 8,128 |
implicated_in | 7,413 |
targets | 6,692 |
involved_in | 4,526 |
prevents | 4,118 |
mediates | 3,811 |
phosphorylates | 3,349 |
degrades | 3,259 |
causal_modulates | 3,133 |
transports | 2,716 |
promotes | 2,517 |
causal_causes | 2,331 |
belongs_to_pathway_cluster | 1,974 |
upregulates | 1,896 |
encodes | 1,839 |
co_expressed_with | 1,730 |
disrupts | 1,399 |
debate_co_mention | 1,381 |
enhances | 1,361 |
stabilizes | 1,131 |
expresses | 1,089 |
risk_factor_for | 1,050 |
causal_prevents | 1,025 |
provides_data_for | 954 |
downregulates | 941 |
causal_extracted | 815 |
references | 755 |
cell_type_involved_in | 702 |
targeted_by | 687 |
binds | 685 |
co_associated_with | 655 |
suppresses | 631 |
involves | 560 |
co_mentioned | 552 |
markers | 545 |
resolved_by | 517 |
mentions | 515 |
decreases_risk | 514 |
affects | 508 |
active_in | 506 |
correlates_with | 403 |
drives | 357 |
accumulates_in | 316 |
produces | 304 |
describes | 290 |
binds_to | 283 |
therapeutic_target_for | 245 |
exacerbates | 241 |
component_of | 228 |
increases_risk | 214 |
reduces | 205 |
protective_against | 198 |
upstream_of | 193 |
targets_gene | 185 |
self_reference | 171 |
predicts | 158 |
impairs | 154 |
investigates | 151 |
modifies | 140 |
participates_in_pathway | 137 |
increases | 135 |
member_of_pathway | 132 |
crosstalk_with | 127 |
expression | 122 |
induces | 109 |
catalyzes | 104 |
part_of | 101 |
cleaves | 92 |
cited_by | 88 |
cites | 88 |
demonstrates | 78 |
depleted_in | 74 |
supports | 74 |
analogous_to | 71 |
member_of | 70 |
linked_to | 64 |
improves | 59 |
metabolizes | 59 |
maintains | 55 |
methylates | 55 |
triggers | 54 |
depletes | 52 |
associated with | 51 |
co_cited_with | 49 |
secreted_by | 49 |
transported_by | 49 |
neuroprotective | 47 |
loss_affects | 46 |
product_of | 46 |
identifies | 45 |
is associated with | 45 |
neurotoxic | 44 |
enables | 43 |
implicates_in | 41 |
precedes | 41 |
attenuates | 40 |
decreases | 40 |
processes | 40 |
releases | 40 |
destabilizes | 39 |
synergizes_with | 39 |
restores | 37 |
facilitates | 36 |
recruits | 34 |
ubiquitinates | 34 |
contributes to | 33 |
translocates_to | 32 |
alters | 30 |
co_mentioned_with | 30 |
documents | 30 |
has_variant | 30 |
downstream_of | 29 |
investigated_in | 29 |
leads to | 29 |
described_by | 28 |
has_wiki | 28 |
involves_gene | 28 |
cross_disease_mechanism_in | 27 |
accelerates | 26 |
alleviates | 26 |
controls | 26 |
is involved in | 26 |
found_in | 25 |
preserves | 25 |
substrate_of | 25 |
ameliorates | 24 |
converts | 24 |
is | 24 |
released_by | 24 |
enriched_in | 22 |
implicates | 22 |
amplifies | 21 |
implicated in | 21 |
addresses_gap | 20 |
contradicts_prediction | 20 |
correlates with | 20 |
is required for | 20 |
differentiates_to | 19 |
NULL | 19 |
type_of | 18 |
has_risk_variant | 17 |
indicates | 17 |
represses | 17 |
cause | 16 |
coexpressed_with | 16 |
influences | 16 |
protects | 16 |
sensitizes_to | 16 |
associates_with | 15 |
generated | 15 |
generates | 15 |
increased | 15 |
interacts with | 15 |
mitigates | 15 |
produced | 15 |
regulate | 15 |
requires | 15 |
secretes | 15 |
stimulates | 14 |
undergoes | 14 |
vulnerable_to | 14 |
related_to | 13 |
required_for | 13 |
risk_factor | 13 |
aggravates | 12 |
associated_with_microglial_priming | 12 |
clears | 12 |
involved in | 12 |
reduced | 12 |
regulated_by | 12 |
relates_to | 12 |
contribute to | 11 |
deacetylates | 11 |
dysregulates | 11 |
is a risk factor for | 11 |
limits | 11 |
localizes_to | 11 |
promote | 11 |
binds to | 10 |
crosses | 10 |
determines | 10 |
essential_for | 10 |
propagates | 10 |
proposes_shared_mechanism | 10 |
damages | 9 |
has | 9 |
impacts | 9 |
increases risk of | 9 |
induce | 9 |
linked to | 9 |
reduce | 9 |
results in | 9 |
sequesters | 9 |
aggregation | 8 |
are involved in | 8 |
attenuated | 8 |
dysregulated_in | 8 |
improved | 8 |
increase | 8 |
initiates | 8 |
mediated_by | 8 |
plays a critical role in | 8 |
plays a role in | 8 |
rescues | 8 |
reverses | 8 |
senses | 8 |
suppressed | 8 |
upregulated_in | 8 |
worsens | 8 |
acetylates | 7 |
activate | 7 |
antagonizes | 7 |
blocks | 7 |
critical_for | 7 |
decreased | 7 |
eliminates | 7 |
induced | 7 |
is characterized by | 7 |
is expressed in | 7 |
is identified as | 7 |
is implicated in | 7 |
is linked to | 7 |
links | 7 |
marker_of | 7 |
mediate | 7 |
models | 7 |
modulate | 7 |
protects against | 7 |
relevant_to | 7 |
used_for | 7 |
ameliorated | 6 |
associates with | 6 |
co_localizes_with | 6 |
competes with | 6 |
compromises | 6 |
correlated with | 6 |
enhance | 6 |
enhanced | 6 |
have | 6 |
lead to | 6 |
may contribute to | 6 |
mechanistic_target | 6 |
projects_to | 6 |
required for | 6 |
acts as | 5 |
aggregates_with | 5 |
bridges | 5 |
co_localizes | 5 |
contains | 5 |
cooperates_with | 5 |
cross-seeds | 5 |
defines | 5 |
deubiquitinates | 5 |
elevated in | 5 |
elevates | 5 |
enriched in | 5 |
expressed in | 5 |
forms | 5 |
increased in | 5 |
influence | 5 |
inhibited | 5 |
is a key regulator of | 5 |
is upregulated in | 5 |
measures | 5 |
normalizes | 5 |
orchestrates | 5 |
present in | 5 |
recognizes | 5 |
relates_to_disease | 5 |
remodels | 5 |
rescued | 5 |
scavenges | 5 |
sustains | 5 |
undergo | 5 |
activated | 4 |
are | 4 |
are associated with | 4 |
are expressed in | 4 |
biomarker_of | 4 |
can lead to | 4 |
caused | 4 |
causes_injury_to | 4 |
contributing to | 4 |
correlate with | 4 |
counteracts | 4 |
creates | 4 |
cross-links | 4 |
delivers | 4 |
depends_on | 4 |
detects | 4 |
distinguishes | 4 |
dysfunction_causes | 4 |
enables_genetic_modification_of | 4 |
engages | 4 |
exerts | 4 |
expressed_on | 4 |
functions as | 4 |
has been linked to | 4 |
impair | 4 |
includes | 4 |
increases_risk_of | 4 |
independent_of | 4 |
induces_transcription | 4 |
inhibit | 4 |
is activated by | 4 |
is a hallmark of | 4 |
is a potential target for | 4 |
is decreased in | 4 |
is highly expressed in | 4 |
is the primary risk factor for | 4 |
localized_to | 4 |
localizes to | 4 |
lowers | 4 |
may be a potential therapeutic target for | 4 |
necessary_for | 4 |
negatively regulates | 4 |
nucleates | 4 |
observed in | 4 |
overlaps | 4 |
performs | 4 |
plays an important role in | 4 |
potentiates | 4 |
prevent | 4 |
prevented | 4 |
regulates_production_of | 4 |
removes | 4 |
repairs | 4 |
represents | 4 |
restored | 4 |
restricts | 4 |
role in | 4 |
serves as | 4 |
showed | 4 |
signals through | 4 |
slows | 4 |
templates | 4 |
used_for_treatment | 4 |
was | 4 |
abolishes | 3 |
accumulates | 3 |
activated_in | 3 |
are enriched in | 3 |
augments | 3 |
belongs to | 3 |
binds directly to | 3 |
biomarker_target | 3 |
boosts | 3 |
breaks down with | 3 |
can reduce | 3 |
causes_aggregation_of | 3 |
causes_degeneration_of | 3 |
causes_loss_of | 3 |
causes_toxicity | 3 |
characterized by | 3 |
co-expressed_with | 3 |
co-localizes | 3 |
contributes | 3 |
coordinates | 3 |
decrease | 3 |
decreased in | 3 |
delays | 3 |
demethylates | 3 |
differentiates | 3 |
directly regulates | 3 |
disrupt | 3 |
disrupted_in | 3 |
downregulated_in | 3 |
elevated | 3 |
exacerbate | 3 |
exhibit | 3 |
exhibits | 3 |
express | 3 |
forms a heterodimer with | 3 |
forms_complex_with | 3 |
found in | 3 |
fuels | 3 |
has essential role in | 3 |
have been implicated in | 3 |
impaired_in | 3 |
inactivates | 3 |
increased under | 3 |
increased with | 3 |
increase risk of | 3 |
increases expression of | 3 |
increases susceptibility to | 3 |
infiltrates | 3 |
is a major contributor to | 3 |
is a major risk factor for | 3 |
is a marker for | 3 |
is a promising target for | 3 |
is a risk locus for | 3 |
is caused by | 3 |
is essential for | 3 |
is expressed by | 3 |
is expressed on | 3 |
is reduced in | 3 |
is the driver of | 3 |
is the most significant risk factor for | 3 |
is the strongest genetic risk factor for | 3 |
leads to reduced | 3 |
lipidates | 3 |
may cause | 3 |
may correlate with | 3 |
mediated | 3 |
mediates_clearance | 3 |
modify | 3 |
not different in | 3 |
occurs_in | 3 |
part of shared mechanisms linking | 3 |
plays a key role in | 3 |
positively correlate with | 3 |
potentiated in | 3 |
prolongs | 3 |
promotes_aggregation_of | 3 |
protected | 3 |
protein_interaction | 3 |
proteolytically_cleaves | 3 |
provides | 3 |
reduces_expression | 3 |
reduces expression of | 3 |
regulated | 3 |
regulates expression of | 3 |
resists | 3 |
resolves | 3 |
responds_to | 3 |
scaffolds | 3 |
selectively_targets | 3 |
serve as | 3 |
shares_mechanism | 3 |
show | 3 |
shows | 3 |
shows a major correlative association with | 3 |
signals downstream of | 3 |
silences | 3 |
studied_in | 3 |
supersedes | 3 |
target | 3 |
transcription_factor_regulates | 3 |
transfers | 3 |
traps | 3 |
underlies | 3 |
underlying | 3 |
upregulated in | 3 |
aberrantly deposited in | 2 |
abrogates | 2 |
accelerate | 2 |
accompanied by | 2 |
accompanies | 2 |
accumulated indels slower than | 2 |
accumulated sSNVs faster than | 2 |
accumulate indels slower than | 2 |
accumulates_at | 2 |
accumulate sSNVs faster than | 2 |
activates_parallel | 2 |
acts as independent biomarker of | 2 |
acts via | 2 |
acutely increased | 2 |
addresses | 2 |
affect | 2 |
affected | 2 |
affects_clearance_of | 2 |
age_related_decline_source | 2 |
aggregates and deposits in | 2 |
aggregates_in | 2 |
agonized_by | 2 |
alleviated | 2 |
altered | 2 |
are categorized as | 2 |
are characterized by | 2 |
are commonly disrupted in | 2 |
are critically dependent on | 2 |
are harmful to | 2 |
are implicated in | 2 |
are important for | 2 |
are increased in | 2 |
are not mediated by | 2 |
are powered by | 2 |
are present in | 2 |
are risk factors for | 2 |
are selectively vulnerable in | 2 |
are tagged with | 2 |
are the nodes of | 2 |
benefits | 2 |
binds and stabilizes | 2 |
binds at the nucleotide pocket of | 2 |
binds_receptor | 2 |
blocks reuptake of | 2 |
bypasses | 2 |
can be genetically modified to express CAR specific for | 2 |
can cause | 2 |
can contribute significantly to | 2 |
can further stimulate | 2 |
can have major effects on | 2 |
causes acceleration of | 2 |
causes (CRISPRa coupled with base editors simultaneously u) | 2 |
causes decrease in | 2 |
causes lysosomal degradation of | 2 |
causes reduction in | 2 |
changes with | 2 |
change their activity with | 2 |
characterized_by | 2 |
colocalizes with | 2 |
communicates_with | 2 |
compensates | 2 |
competes_with | 2 |
complements | 2 |
composes | 2 |
comprises | 2 |
connected with | 2 |
consists primarily of | 2 |
contributes to fibrillization of | 2 |
controls_cell_fate_via_crosstalk | 2 |
converges_with | 2 |
converts_to | 2 |
co_occurs | 2 |
co_occurs_with | 2 |
could affect | 2 |
could be precipitating a cascade of events leading to | 2 |
could contribute to | 2 |
could provide effective treatment for | 2 |
counteract | 2 |
counteracts the effects of | 2 |
crossed | 2 |
decreases disease severity in a dose-dependent manner | 2 |
decreases_with | 2 |
demonstrated sustained target engagement in | 2 |
depends on | 2 |
destabilizes_closed_state | 2 |
detected in | 2 |
determine risk of developing | 2 |
did not reduce | 2 |
diminishes | 2 |
directly activates | 2 |
directly interacts with and phosphorylates | 2 |
directs transcription of genes defining | 2 |
disaggregates | 2 |
distinct_from | 2 |
does not associate with | 2 |
does_not_cause | 2 |
does not predispose to | 2 |
driven by | 2 |
driver of | 2 |
driving the release of | 2 |
elevate | 2 |
encodes_subunit_of | 2 |
encompasses | 2 |
engineered to identify and eliminate | 2 |
enhances microglia phagocytosis of | 2 |
enriches | 2 |
enters_cells_via | 2 |
epigenetic_regulation | 2 |
excludes | 2 |
exerts cell non-autonomous effect on | 2 |
exhibit decrease in | 2 |
exhibit distinct 3D genome organization compared to | 2 |
exhibited | 2 |
exhibits pathological synergy with | 2 |
expressed by | 2 |
extends | 2 |
facilitated | 2 |
formed puncta in | 2 |
forms receptor signaling complex with | 2 |
functionally_coupled_to | 2 |
functions_together_with | 2 |
generate | 2 |
genetic modifier of | 2 |
had marginal effect on | 2 |
has an important link with | 2 |
has been implicated in | 2 |
has been proven to be a major contributor to | 2 |
has been shown to interact with | 2 |
has crucial role in | 2 |
has emerged as | 2 |
has isolated effects on | 2 |
has neuroprotective roles in | 2 |
has potential as | 2 |
has potential for treating | 2 |
has potential in preventing and treating | 2 |
has role in | 2 |
has significant genetic correlation with | 2 |
have a bidirectional relationship with | 2 |
have a role in | 2 |
have distinct responses to | 2 |
have diverse functions at | 2 |
have effect sizes ~10 times larger than | 2 |
have limited efficacy against due to | 2 |
hyperphosphorylates | 2 |
identified patients for | 2 |
identifies_regulators_of | 2 |
impairs formation and function of | 2 |
impede | 2 |
improve | 2 |
increases risk for | 2 |
increases risk for developing | 2 |
increase the risk for developing | 2 |
induced by | 2 |
induced in | 2 |
induces downregulation of | 2 |
induces_formation_of | 2 |
induces_transcriptional_reprogramming_via | 2 |
inhibits_overactivation | 2 |
inhibits_removal_of | 2 |
interact with | 2 |
interact with and cause | 2 |
interferes with | 2 |
is a | 2 |
is a convergent hallmark of | 2 |
is a direct checkpoint inhibitor of | 2 |
is age-associated and occurs before | 2 |
is a genetic modifier of | 2 |
is age-regulated in | 2 |
is a humanized monoclonal immunoglobulin G4 antibody targeting | 2 |
is altered in | 2 |
is a modification of | 2 |
is an early step in | 2 |
is an endogenous substrate of | 2 |
is an important target for | 2 |
is an independent risk factor for | 2 |
is an inhibitor of | 2 |
is a novel druggable target for | 2 |
is a positive regulator of | 2 |
is a potential target in | 2 |
is a predictive marker for | 2 |
is a substrate of | 2 |
is a target for | 2 |
is connected with | 2 |
is considered the disease-causative mechanism of | 2 |
is converted to | 2 |
is critical for | 2 |
is degraded in | 2 |
is down-regulated in | 2 |
is downregulated in | 2 |
is expressed outside | 2 |
is genetically linked to | 2 |
is genetic risk factor for | 2 |
is important for | 2 |
is important in | 2 |
is increased in | 2 |
is independent biomarker of | 2 |
is instrumental in mediating | 2 |
is involved in maintaining | 2 |
is key early pathological process in | 2 |
is leading cause of | 2 |
is lipidated via | 2 |
is lower in | 2 |
is mainly expressed in | 2 |
is mediated by | 2 |
is not required for | 2 |
is potential target for | 2 |
is potential treatment for | 2 |
is present in | 2 |
is preserved in | 2 |
is recruited to | 2 |
is required for basal transcription of | 2 |
is required for optimal release of | 2 |
is responsible for | 2 |
is restricted to | 2 |
is the catalytic site of | 2 |
is the most important modifiable risk factor for | 2 |
is the primary lipid carrier within | 2 |
is the principal correlate of | 2 |
is the strongest genetic risk factor associated with | 2 |
is the strongest predictor for | 2 |
is ultimately converted to | 2 |
is vital for maintaining | 2 |
leads_to | 2 |
leads to increase in | 2 |
limits diffusion of CAR T cells across | 2 |
limits efficacy of CAR T cells against | 2 |
linked with | 2 |
localizes to inclusions in | 2 |
located_in | 2 |
loses capacity to bind | 2 |
loss-of-function results in | 2 |
marks | 2 |
may be | 2 |
may be important as a therapeutic target in | 2 |
may be involved in | 2 |
may block the reuptake of | 2 |
may impact | 2 |
may increase | 2 |
may induce | 2 |
may mechanistically explain | 2 |
may mediate | 2 |
may modify risk for | 2 |
may play a role in | 2 |
may serve as | 2 |
mediated by | 2 |
mediates downregulation of | 2 |
mediates protein stabilization of | 2 |
mediates uptake of | 2 |
mimics | 2 |
misfunctions to precipitate | 2 |
mislocalizes to | 2 |
modification of | 2 |
modulating the aggregation and clearance of | 2 |
more readily recruited to the Golgi and activated by | 2 |
negatively correlated with | 2 |
negatively_regulates | 2 |
normally associates with and stabilizes | 2 |
occurs in brain regions with high | 2 |
offers mitochondria-targeting strategy for treatment of | 2 |
palmitoylates | 2 |
partially_agonizes | 2 |
participate in | 2 |
participates in | 2 |
pathological_aggregation | 2 |
penetrates | 2 |
permits | 2 |
perturbs | 2 |
phagocytoses | 2 |
phagocytosis | 2 |
phosphorylates_at_T217 | 2 |
play role in | 2 |
plays a crucial role in modulating | 2 |
plays a crucial role in the regulation of | 2 |
plays an essential role in developing | 2 |
plays a prominent role in | 2 |
plays a significant role in | 2 |
plays crucial role in | 2 |
plays essential role in | 2 |
positively correlated with | 2 |
potential effective modulator for | 2 |
predicted | 2 |
preserved | 2 |
promoted | 2 |
promotes formation of | 2 |
promotes K63-linked ubiquitination of | 2 |
promotes pro-survival autophagy by inhibiting | 2 |
protected against | 2 |
provides evidence for cell-autonomous disease initiation in | 2 |
provokes | 2 |
reactivates | 2 |
re-administered to identify and eliminate | 2 |
recruited_to | 2 |
reduces AD pathology by inhibiting | 2 |
reflects | 2 |
regulates autophagy by deubiquitinating | 2 |
regulates_expression | 2 |
related to | 2 |
remodeled | 2 |
represent | 2 |
repression | 2 |
reprograms | 2 |
required | 2 |
result in | 2 |
selectively_removes | 2 |
sensitizes | 2 |
serves_as | 2 |
serves as essential cofactor for | 2 |
severely_impairs | 2 |
shape | 2 |
shapes | 2 |
show decreased | 2 |
show increase in metabolism associated with | 2 |
shows no | 2 |
signals | 2 |
signals_through | 2 |
significantly reduced | 2 |
spreads via | 2 |
stimulate | 2 |
stimulated | 2 |
strengthened | 2 |
suppress | 2 |
suppressed_by | 2 |
suppressed phosphorylation of | 2 |
suppresses generation of | 2 |
suppression_promotes | 2 |
synergizes | 2 |
synthesizes | 2 |
target for | 2 |
transcriptionally_regulates | 2 |
transfers mitochondria to | 2 |
transitions_to | 2 |
transmitted_to | 2 |
treat | 2 |
trigger | 2 |
upregulated | 2 |
uses | 2 |
utilizes perivascular tunnels formed by | 2 |
was associated with higher | 2 |
was critical for | 2 |
was decreased in | 2 |
was increased in | 2 |
was not associated with | 2 |
worsens with | 2 |
would not be restricted to | 2 |
: | 1 |
abnormally elevated in | 1 |
abolished | 1 |
abundant in | 1 |
accelerates onset by | 1 |
access to the central nervous system is restricted by | 1 |
account for the majority of cases of | 1 |
accrues more tau inclusions in | 1 |
accumulate_at | 1 |
accumulated in | 1 |
accumulate during | 1 |
accumulates in | 1 |
accumulates_intraneuronally | 1 |
accumulates more tau inclusions in | 1 |
accumulates mostly in | 1 |
accumulate somatic mutations linearly with | 1 |
accurately predict | 1 |
achieved treatment effect in | 1 |
achieves | 1 |
achieves in AIBL cohort | 1 |
acquire | 1 |
act as templates for | 1 |
acted as independent biomarkers of | 1 |
activated_by | 1 |
activates antioxidant defenses via | 1 |
activates_collisional_sensor | 1 |
activates transcription of | 1 |
activates transcription via | 1 |
activates_via_MT1_ERK_signaling | 1 |
Activate TREM2 signaling pathways to reprogram microglia from tau-propagating phenotype to tau-clear | 1 |
acts as a key relay of | 1 |
acts as a positive allosteric modulator of | 1 |
acts as a regulator of | 1 |
acts as a signaling molecule of modulating | 1 |
acts as critical driver of | 1 |
acts as denominator in | 1 |
acts as functional inhibitor of | 1 |
acts as key fine-tuner and amplifier of | 1 |
acts as mixed inhibitor of | 1 |
acts by tuning | 1 |
acts in the | 1 |
acts_on | 1 |
acts through | 1 |
acts_upstream_of | 1 |
acylates | 1 |
adds a layer to | 1 |
adds value to | 1 |
adjusts | 1 |
adopts folded-back configuration that keeps itself inactive through | 1 |
affected differently | 1 |
affected_in | 1 |
affect indirectly by impacting | 1 |
affects preferentially | 1 |
affects the biogenesis of | 1 |
aids_in_understanding | 1 |
aim to rescue | 1 |
aim to restore | 1 |
aligned event of | 1 |
aligned with | 1 |
align with | 1 |
alleviated BBB damage by increasing expression of | 1 |
alleviates BBB damage by increasing | 1 |
allosterically activates | 1 |
allows cancer cells to escape | 1 |
allows for precise correction of | 1 |
allows precise correction of | 1 |
always formed | 1 |
always had | 1 |
always required for | 1 |
amplified_in | 1 |
amplifies GPC4-mediated | 1 |
anticipate | 1 |
appear distinct from | 1 |
appears essential to | 1 |
appears in | 1 |
appears in brain regions with | 1 |
appears to play a role in | 1 |
appears to successfully mitigate | 1 |
appear to be affected in | 1 |
appear to be particularly sensitive to | 1 |
appear to estimate | 1 |
are abundant in | 1 |
are accompanied by | 1 |
are a common cause of | 1 |
are activated by | 1 |
are affected in | 1 |
are age dependent in | 1 |
are altered with | 1 |
are amplified by | 1 |
are an important feature in | 1 |
are a potential source for | 1 |
are at greatest risk for | 1 |
are being investigated for | 1 |
are broadening the phenotype associated with | 1 |
are causative genes for | 1 |
are closely associated with | 1 |
are critical during | 1 |
are critically involved in | 1 |
are crucial for | 1 |
are decreased in | 1 |
are degraded by | 1 |
are dependent on | 1 |
are dependent upon | 1 |
are disrupted by | 1 |
are effective for | 1 |
are effective for treating | 1 |
are emerging as key players in | 1 |
are essential to | 1 |
are features of | 1 |
are_for_treatment_of | 1 |
are fundamental to | 1 |
are hallmark of | 1 |
are heterogeneous in | 1 |
are highly expressed by | 1 |
are highly expressed in | 1 |
are hypomethylated in | 1 |
are implicated in the pathogenesis of | 1 |
are important drivers of | 1 |
are in clinical development for | 1 |
: are increased in colocalization with | 1 |
are induced by | 1 |
are key mediators of | 1 |
are key pathogenic players in | 1 |
are less tolerant to | 1 |
are linked to | 1 |
are lower than | 1 |
are manifestations of | 1 |
are metabolized into | 1 |
are modifiers of | 1 |
are mutated in | 1 |
are necessary and sufficient to induce | 1 |
are necessary but not sufficient to generate | 1 |
are negatively associated with | 1 |
are new risk loci for | 1 |
are not directly aware of | 1 |
are not required for | 1 |
are novel genes for | 1 |
are observed in | 1 |
are particularly sensitive to | 1 |
are postulated to be determinants of | 1 |
are potential targets for | 1 |
are potential targets in | 1 |
are promising therapeutic targets to restore | 1 |
are reduced in coverage on | 1 |
are referred to as | 1 |
are repaired in | 1 |
are required for | 1 |
are responsible for directly life-threating conditions such as | 1 |
are specifically enriched in | 1 |
are specific risk factors for | 1 |
are spontaneously regenerative after | 1 |
are sufficient to induce | 1 |
are tagged with complement proteins and consequently removed by | 1 |
are the main cell type presenting aggregates composed of | 1 |
are the most common known cause of | 1 |
are the pathological hallmark of | 1 |
are therapeutic strategies for | 1 |
are the reason to seek medical attention in | 1 |
are thought to be related to | 1 |
are trapped in transition to the fully reactive state without | 1 |
are uniquely vulnerable to | 1 |
arise from | 1 |
assists in the full glycosylation of | 1 |
associated with and was activated by | 1 |
associated with decreased activation of | 1 |
associated with higher levels of | 1 |
associated with higher proportions in | 1 |
associated_with_higher_tone | 1 |
associated with improved outcomes in | 1 |
associated with increased activation of | 1 |
associated with increased risk for | 1 |
associated with increased risk of | 1 |
associated with pathophysiological changes | 1 |
associates with and is activated by | 1 |
associates with stress granules by interacting with via | 1 |
associates with stress granules via interacting with | 1 |
astrocyte_response_linked_to | 1 |
attains in ADNI cohort | 1 |
attenuate | 1 |
attenuated and reversed | 1 |
attenuated by stimulating | 1 |
attenuates declines in | 1 |
attracted attention as | 1 |
attracts | 1 |
attributes a pivotal role to | 1 |
augment | 1 |
autoregulates | 1 |
backs_up | 1 |
bacterial_enzyme | 1 |
balances | 1 |
become more abstract or symbolic at later stages of | 1 |
becomes downregulated following | 1 |
becomes increasingly sensitized in | 1 |
begins to accumulate within | 1 |
beneficial_for | 1 |
benefits_for | 1 |
biases | 1 |
binds_and_degrades | 1 |
binds competitively with and interacts with | 1 |
binds in association with | 1 |
binds more weakly to | 1 |
binds to acetylated histones and directs transcription of | 1 |
binds to promoter of | 1 |
binds_weakly | 1 |
bind to and become trapped by | 1 |
biomarker for | 1 |
blocked | 1 |
blocks the reuptake of | 1 |
blood-brain_barrier_penetration_limitation | 1 |
blunted | 1 |
buffer | 1 |
buffers | 1 |
can alter | 1 |
can arise from | 1 |
can arise from multiple cellular states along | 1 |
can be altered by | 1 |
can be assigned to | 1 |
can be cast as | 1 |
can be cast faithfully as | 1 |
can be coprecipitated with | 1 |
can be diagnosed in | 1 |
can be diagnosed in individuals with | 1 |
can be dissociated from | 1 |
can be exploited for | 1 |
can be genetically modified to express | 1 |
can be inferred from | 1 |
can be similarly discriminated with | 1 |
can be strongly nonlinear when the inhibitory battery is near the resting potential in | 1 |
can be used to infer | 1 |
can be used to monitor | 1 |
can be used to track | 1 |
can be useful in modeling | 1 |
can directly link | 1 |
can enhance | 1 |
can enter and exit | 1 |
can function as | 1 |
can improve | 1 |
can increase | 1 |
can_induce | 1 |
can neutralize when expressed as | 1 |
cannot be attributed to | 1 |
cannot be concluded ineffective for | 1 |
cannot interact with | 1 |
can occur | 1 |
can perform as | 1 |
can play a significant role in the MSc pathogenesis that results in | 1 |
can precisely control | 1 |
can prevent | 1 |
can reflect | 1 |
can rescue | 1 |
can secrete and respond to | 1 |
can theoretically be treated but | 1 |
caps | 1 |
captures | 1 |
carries | 1 |
catalysis | 1 |
catalytic_activity | 1 |
catalyzes the esterification of | 1 |
catalyzes_ubiquitination_of | 1 |
causative_ratio | 1 |
caused by | 1 |
cause deficits in | 1 |
caused reductions in | 1 |
caused resistance to | 1 |
cause reduction in | 1 |
causes (14-3-3 protein binding to phospho-TFEB improves tr) | 1 |
causes (27-hydroxycholesterol promotes oligodendrocyte mat) | 1 |
causes (30-50% reduction in somatic CAG expansion leads to) | 1 |
causes absence of | 1 |
causes_accumulation_of | 1 |
causes (activated TNFRSF25 accelerates cognitive decline i) | 1 |
causes activation of | 1 |
causes (adult-onset CNS myelin sulfatide deficiency is suf) | 1 |
causes (aged brain exosomes specifically activate neuronal) | 1 |
causes (age-related activation of cGAS-STING drives microg) | 1 |
causes (age-related CD300f dysfunction allows excessive ne) | 1 |
causes (age-related cytokine secretion specifically suppre) | 1 |
causes (age-related decline in microglial profilin-1 disru) | 1 |
causes (age-related downregulation of AP1S1 disrupts clath) | 1 |
causes (aging activation of microglia leads to increased C) | 1 |
causes (aging causes early transcriptomic changes in oligo) | 1 |
causes (aging mitochondrial dysfunction triggers STING pat) | 1 |
causes_alterations_in | 1 |
causes (altered glia-neuron communication in Alzheimer's D) | 1 |
causes (APOE4 C130R mutation is disease-associated while A) | 1 |
causes (APOE4 disrupts lipid metabolism and synaptic suppo) | 1 |
causes (APOE4 mediates myelin breakdown by targeting oligo) | 1 |
causes_apoptosis_of | 1 |
causes (APP overexpression causes selective vulnerability ) | 1 |
causes (astrocyte-derived inflammatory signals aberrantly ) | 1 |
causes (astrocyte-specific APOE4 knockout may worsen outco) | 1 |
causes (astrocytic APOE4 drives synaptic phagocytosis by m) | 1 |
causes (CaMKII-dependent process that promotes spine gener) | 1 |
causes (CaMKII enhancement promotes dendrite ramification ) | 1 |
causes (causes cell death through lysosomal membrane perme) | 1 |
causes_changes_in | 1 |
causes (chronic hypoperfusion leads to pericyte-derived BM) | 1 |
causes (complete APOE4 removal may disrupt normal lipid ho) | 1 |
causes (complex I defects are found in substantia nigra ne) | 1 |
causes_contraction | 1 |
causes/contributes to | 1 |
causes (converting disease-associated APOE4 to protective ) | 1 |
causes (coordinated dysfunction across astrocyte-microglia) | 1 |
causes (creates a feed-forward loop of neuroinflammation l) | 1 |
causes (CRISPRa with chromatin modifiers can reactivate si) | 1 |
causes (CXCL10 acts as chemokine to recruit cytotoxic CD8+) | 1 |
causes (CXCL10 antagonists would preserve white matter int) | 1 |
causes cytoplasmic destruction of | 1 |
causes_damage_to | 1 |
causes_deficits_in | 1 |
causes delay in | 1 |
causes destruction of | 1 |
causes (disease-associated microglia show dysregulated TRE) | 1 |
causes disease through | 1 |
causes (disrupted cytoskeletal checkpoints lead to prematu) | 1 |
causes (disrupted endosomal-lysosomal trafficking creates ) | 1 |
causes (disrupted WNT signaling affects inhibitory interne) | 1 |
causes (DNA damage in oligodendrocytes precedes amyloid pa) | 1 |
causes (dysfunction precedes and triggers compensatory TFE) | 1 |
causes (dysregulated ISR in vulnerable neurons leads to pr) | 1 |
causes (dysregulated microglial transitions fail to suppor) | 1 |
causes (early enhancement prevents pathology by promoting ) | 1 |
causes (early proteasome downregulation and dysfunction dr) | 1 |
causes emergence of | 1 |
causes (energy metabolism disorders cause Parkinson's dise) | 1 |
causes (enhanced ACE expression in microglia increases Aβ ) | 1 |
causes (enhances proton pumping to restore acidic pH in ly) | 1 |
causes (enhances TFEB activity to promote selective cleara) | 1 |
causes (enhancing TREM2 expression activates microglia and) | 1 |
causes (environmental stressors induce energy metabolism d) | 1 |
causes (epigenetic silencing of neuroprotective genes occu) | 1 |
causes escape from | 1 |
causes escape from osimertinib and initiates | 1 |
causes (excessive complement activation leads to neurotoxi) | 1 |
causes failure of | 1 |
causes/impaired expression leads to | 1 |
causes_impairment | 1 |
causes increased | 1 |
causes (increased autophagy leads to lysosomal overload an) | 1 |
causes increases in | 1 |
causes (induces autophagy through multiple pathways includ) | 1 |
causes (iron-dependent ferroptosis contributes to α-synucl) | 1 |
causes (ischemic conditions induce autophagy pathway activ) | 1 |
causes (loss of natural sensory input leads to degeneratio) | 1 |
causes (loss of sulfatides removes suppression of microgli) | 1 |
causes (microglia activate CXCL10-mediated recruitment of ) | 1 |
causes (microglial ACE enhancement activates spleen tyrosi) | 1 |
causes (microglial activation orchestrates CXCL10-mediated) | 1 |
causes (mitochondrial dysfunction is central to ALS pathog) | 1 |
causes (MSH3 drives somatic expansion of HTT CAG repeats t) | 1 |
causes (myelin sulfatide deficiency causes cognitive impai) | 1 |
causes (NAD+ supplementation improves mitophagy and mitoch) | 1 |
causes (NMDA receptors mediate synaptic depression in amyl) | 1 |
causes (NOMO1 function improves endoplasmic reticulum home) | 1 |
causes (oligodendrocyte dysfunction leads to loss of myeli) | 1 |
causes (optogenetic activation selectively restores gamma ) | 1 |
causes (optogenetic activation selectively restores theta ) | 1 |
causes (PARP1 activation enhances base excision repair pat) | 1 |
causes (pericyte-derived BMP4 causes white matter damage a) | 1 |
causes (PMS1 drives somatic expansion of HTT CAG repeats t) | 1 |
causes (prevents energy needed for enhanced autophagy desp) | 1 |
causes (prevents enzyme function despite increased biogene) | 1 |
causes (promotes contact sites that enable energy-dependen) | 1 |
causes (protein aggregation drives cell-to-cell spreading ) | 1 |
causes (proteostasis failure leads to protein aggregation ) | 1 |
causes (recruited CD8+ T cells promote aging-related white) | 1 |
causes (recruited CD8+ T cells promote white matter degene) | 1 |
causes reduced | 1 |
causes reductions in | 1 |
causes (selective CXCR3 blockade could preserve white matt) | 1 |
causes (selective downregulation of MSH3 creates temporal ) | 1 |
causes (selective modulation of GluN2B-containing NMDA rec) | 1 |
causes (selective noradrenaline depletion exacerbates syna) | 1 |
causes (selective removal of astrocytic APOE4 strongly pro) | 1 |
causes (selective silencing may trigger compensatory mecha) | 1 |
causes (senescence creates a self-perpetuating cycle by pr) | 1 |
causes_sensitivity_to | 1 |
causes (specifically disrupt parvalbumin-positive interneu) | 1 |
causes (specifically disrupt somatostatin-positive interne) | 1 |
causes (STING activation leads to cellular senescence and ) | 1 |
causes stress-induced pathogenic increase in | 1 |
causes (suppressed mitochondrial function creates vulnerab) | 1 |
causes (tau aggregation triggers cellular senescence respo) | 1 |
causes (tau pathology spreads from locus coeruleus to hipp) | 1 |
causes toxicity to | 1 |
causes (VIP interneuron-mediated disinhibition allows pyra) | 1 |
central_in | 1 |
changes | 1 |
changes expression profiles of | 1 |
changes levels of | 1 |
changes more rapidly | 1 |
characterizes | 1 |
CHMP4B modulates tau_propagation | 1 |
circadian_entrainment_target | 1 |
circadian_phase_anchoring | 1 |
claimed_Gq11_coupling_target | 1 |
clear | 1 |
clearance_mechanism_for | 1 |
clearance_of | 1 |
cleared_by | 1 |
cleavage_product | 1 |
cleaved_by | 1 |
cleaves_tight_junction | 1 |
cleaves_tight_junction_protein | 1 |
cleaves_to_produce | 1 |
closely associate with | 1 |
closes | 1 |
cns_penetration_limitation | 1 |
co-aggregates_with | 1 |
coats | 1 |
co_chaperone | 1 |
codes_for_subunit | 1 |
co-expressed in | 1 |
collectively regulate | 1 |
colocalized and bound | 1 |
co_localizes_in | 1 |
colocalizes_in | 1 |
co-localizes with | 1 |
co-localizes_with | 1 |
colocalizes_with | 1 |
co-localize with | 1 |
combines with | 1 |
communicates bidirectionally with | 1 |
communicate with | 1 |
comorbid_with | 1 |
compartmentalized within | 1 |
compensate for | 1 |
completely blocks | 1 |
complexes with and stabilizes | 1 |
complex with | 1 |
complicates | 1 |
concentrates | 1 |
confer risk for | 1 |
confers atheroprotection by binding to | 1 |
confers increased risk for | 1 |
confers protection against | 1 |
confers_resistance | 1 |
confers resistance to | 1 |
confers via | 1 |
confer toxic functions that impair | 1 |
conjugates | 1 |
connect | 1 |
connects_to | 1 |
constitutes | 1 |
contain | 1 |
contained | 1 |
contains sequence similarities to | 1 |
continues | 1 |
contradicted_by_trial_failure | 1 |
contributed to inflammation through | 1 |
contributes independent information as a predictor of | 1 |
contributes_to_development | 1 |
contributes to risk for | 1 |
contributes to the degradation of | 1 |
contributes to weakening | 1 |
contributes to weakening metabolic state by interfering with | 1 |
control | 1 |
controls the flow of | 1 |
controls through negative feedback loop | 1 |
converge in | 1 |
converge on a common mechanism with | 1 |
converge on common mechanism with | 1 |
converges_on | 1 |
converge upon | 1 |
converted | 1 |
co-occurs with | 1 |
cooperates | 1 |
co-regulate in | 1 |
co_regulates | 1 |
co-regulates_clearance_with | 1 |
co-released with | 1 |
co-release glycine and | 1 |
core_protein_of | 1 |
correct | 1 |
correlated_trajectory_with | 1 |
correlated with preservation of | 1 |
correlate negatively with | 1 |
correlates better with | 1 |
correlates negatively with | 1 |
corresponds with enhanced extracellular | 1 |
co-stimulates | 1 |
co-traffics_with | 1 |
could be an effective approach to control | 1 |
could be a new molecular target in | 1 |
could be beneficial for | 1 |
could be beneficial in | 1 |
could be effective therapy for | 1 |
could be mechanistically important in | 1 |
could depend on | 1 |
could help select | 1 |
could hypothetically have a role in shaping | 1 |
could mark a turning point in | 1 |
could potentially contribute to | 1 |
could provide effective treatment option for | 1 |
could reduce | 1 |
could relate to | 1 |
could remodel | 1 |
coupled_with | 1 |
couples | 1 |
couples_with | 1 |
covalent_cross-linking | 1 |
covalently_cross-links | 1 |
cover | 1 |
creates hotspots for | 1 |
critical_in | 1 |
critically controls | 1 |
critically determine | 1 |
critically regulates | 1 |
crosses and targets | 1 |
cross_links | 1 |
culminates in | 1 |
cytotoxic_T_cell | 1 |
damage | 1 |
dampen | 1 |
dampened | 1 |
dampens | 1 |
dampens_serum_half_life | 1 |
deacetylation | 1 |
deactivates | 1 |
decay exponentially during | 1 |
declined with | 1 |
declines during | 1 |
declines_during | 1 |
declines_faster_than | 1 |
declines_with | 1 |
decreased accumulation of | 1 |
decreased_by | 1 |
decreased_expression_in | 1 |
decreased on | 1 |
defers | 1 |
deficiency_causes | 1 |
defines histopathologically | 1 |
defines the seed for | 1 |
degenerates_in | 1 |
degraded_by | 1 |
degraded via | 1 |
delay | 1 |
delayed | 1 |
delaying | 1 |
delays_onset | 1 |
demonstrated highest significance among | 1 |
demonstrated safety and potential efficacy for | 1 |
demonstrated sustained target engagement and pharmacodynamic responses in | 1 |
demonstrates infectivity in | 1 |
demonstrates neurotoxic and neuroprotective action by | 1 |
dependent_on | 1 |
dephosphorylates | 1 |
dephosphorylates and triggers nuclear translocation of | 1 |
depletes via mGluR5-mediated mechanism | 1 |
depletion_impairs_ubiquitylation | 1 |
Deploy selective small molecule inhibitors targeting the tau-binding domain of LRP1 to prevent cellu | 1 |
deposits | 1 |
desensitization_mechanism | 1 |
Design allosteric modulators that specifically enhance HSP90's tau disaggregation activity without a | 1 |
designed to clear | 1 |
Design selective allosteric activators of VCP/p97 ATPase activity specifically for tau-containing au | 1 |
destroys | 1 |
de-SUMOylates | 1 |
detects_glymphatic_dysfunction | 1 |
detects_neuroaxonal_injury | 1 |
determine availability of | 1 |
determines risk of developing | 1 |
deubiquitinates and stabilizes | 1 |
deubiquitinating | 1 |
develops | 1 |
Develop selective modulators of neurexin-neuroligin interactions to create synaptic barriers that pr | 1 |
did not affect | 1 |
did not alter | 1 |
did not demonstrate efficacy in preventing | 1 |
did not directly reach | 1 |
did not identify new | 1 |
did not increase the risk of | 1 |
did not lower | 1 |
did not meet primary endpoint of change from baseline in | 1 |
did not result in significant differences in improvement in | 1 |
did not show significant effect on | 1 |
did not show significant mediation effects on | 1 |
did not significantly improve | 1 |
differentially affects | 1 |
differentially binds to | 1 |
differentially modulates | 1 |
differs between | 1 |
diminished | 1 |
direct acquisition of | 1 |
directly acts on | 1 |
directly binds and enhances splicing of | 1 |
directly binds to | 1 |
directly controls | 1 |
directly controls NO production by interacting with | 1 |
directly interacted with | 1 |
directly interacts with | 1 |
directly leads to | 1 |
directly or indirectly damages | 1 |
directly promoted | 1 |
directly promoted expression of | 1 |
directly triggers | 1 |
directs | 1 |
directs the location of | 1 |
directs transcription of | 1 |
disassemble and/or degrade | 1 |
disassembles | 1 |
discovered | 1 |
discovered in | 1 |
discriminates between | 1 |
disengaged from | 1 |
disinhibits | 1 |
displaces | 1 |
display | 1 |
display activity related to | 1 |
display compartment switches and are strongly correlated with | 1 |
display downregulation of | 1 |
displays | 1 |
display unique susceptibility to | 1 |
disproportionately expanded in | 1 |
disrupted | 1 |
disrupts the functions of | 1 |
distinguished by | 1 |
distinguishes and marks | 1 |
disturbs_interaction_with | 1 |
does_not_address | 1 |
does_not_affect | 1 |
does not alter | 1 |
does not appear to be associated with | 1 |
does not cause destruction of | 1 |
does not compensate for | 1 |
does_not_detect | 1 |
does not impair | 1 |
does not result in | 1 |
does not significantly affect | 1 |
does not significantly improve | 1 |
does not worsen | 1 |
dominant_negative_effect | 1 |
donepezil_target | 1 |
do not correlate with | 1 |
do not have overlapping functions in | 1 |
do not show atrophy despite marked amyloid accumulation | 1 |
do not show predisposition to | 1 |
down-regulate | 1 |
downregulated | 1 |
downregulated in | 1 |
down-regulates | 1 |
downstream effector of | 1 |
drives_elevation_via | 1 |
drives_formation | 1 |
drives_formation_of | 1 |
drives_nuclear_translocation_of | 1 |
drives_phase_separation | 1 |
drives the release of | 1 |
driving force in | 1 |
drug_target | 1 |
dysregulated | 1 |
dysregulation_associated_with | 1 |
dysregulation in | 1 |
early_event | 1 |
early_vulnerability | 1 |
ectodomain_shedding | 1 |
effective in/contraindicated in | 1 |
effect_on | 1 |
effector_of | 1 |
effects | 1 |
efficiently transfected | 1 |
elevated by | 1 |
elevated_in | 1 |
elicits | 1 |
elicits memory lymphocytes that persist and display functional hallmarks of | 1 |
emerged as | 1 |
emerging as a key factor in | 1 |
enables_control_of | 1 |
enables effective degradation via | 1 |
enables elimination of | 1 |
enables resilience to | 1 |
encoded_by | 1 |
encode proteins involved in | 1 |
encodes a core component essential for | 1 |
encodes a protein that regulates | 1 |
encodes_component | 1 |
encodes core component of | 1 |
encodes_ligand_for | 1 |
engineers | 1 |
enhanced_by | 1 |
enhanced expression of | 1 |
enhanced the transcription of | 1 |
enhanced transcription of | 1 |
enhances activation of | 1 |
enhances and suppresses | 1 |
enhances_clearance | 1 |
enhances endurance and reduces fatigue in | 1 |
enhances_function | 1 |
enhances mitochondria biogenesis by acting on | 1 |
enhances neuronal excitability and promotes | 1 |
enhances_release | 1 |
enhances slicing of | 1 |
enhances the association with | 1 |
enhances transcription of | 1 |
enriched for | 1 |
ensures rapid increase in | 1 |
enters | 1 |
enters_via | 1 |
epigenetically alters | 1 |
epistasis_with | 1 |
erases | 1 |
essential for | 1 |
establish | 1 |
established as genetic risk factors for | 1 |
established at conception and heightened during adolescence and midlife may partially embed | 1 |
establishes | 1 |
evoked | 1 |
exacerbated | 1 |
exacerbate or mitigate | 1 |
exacerbates_through_upregulating_Survivin | 1 |
exacerbating | 1 |
exerted anti-neuroinflammatory effects through regulation of | 1 |
exert neuroprotective effect against | 1 |
exerts an inhibitory effect on | 1 |
exerts anti-inflammatory effect on | 1 |
exerts_negative_feedback | 1 |
exerts neuroprotective effect in ischemia through | 1 |
exerts neuroprotective effects by promoting | 1 |
exerts neuroprotective effect through | 1 |
exerts neuroprotective properties that are strongly implicated in reducing | 1 |
exerts protective role against | 1 |
exerts top-down executive control over | 1 |
exhibit a hypermetabolic phase before hypometabolism | 1 |
exhibit almost undetectable | 1 |
exhibit cell type-specific | 1 |
exhibit cell-type specific tropism in | 1 |
exhibit decreased | 1 |
exhibited dose-response correlated with | 1 |
exhibited improved | 1 |
exhibited longer treatment-response durations to | 1 |
exhibited persistent delay activity that predicted | 1 |
exhibited reduced | 1 |
exhibited selective persistent delay activity that predicted | 1 |
exhibit extreme diversity in | 1 |
exhibit higher | 1 |
exhibit remyelination response in | 1 |
exhibits_differences_in | 1 |
exhibits_E3_ligase_activity_for | 1 |
exhibits hallmark neuropathology in | 1 |
exhibits preference for | 1 |
exhibits significant correlation with | 1 |
exhibits_specificity_for | 1 |
exist in dynamic equilibrium between | 1 |
exits nucleus in | 1 |
expands from | 1 |
exploits | 1 |
exposes | 1 |
express and activate | 1 |
expressed primarily in | 1 |
expressed receptors capable of neutralizing | 1 |
expressed selectively by | 1 |
expresses_in | 1 |
extending beyond the boundaries of the cell and influencing | 1 |
extends_persistence | 1 |
: facilitated recruitment of | 1 |
facilitates bidirectional communication between | 1 |
facilitates brain-wide distribution of | 1 |
facilitates_degradation_via_TRIM21 | 1 |
facilitates diagnosis of | 1 |
facilitates_nuclear_export_of | 1 |
facilitates proteostasis by promoting degradation of | 1 |
facilitates proteostasis of | 1 |
facilitates recovery from | 1 |
facilitates tau aggregate uptake and seeding in | 1 |
facilitates_transmission_of | 1 |
facilitates_transport | 1 |
failed_clinical_trial | 1 |
failed_therapeutic | 1 |
failed to demonstrate efficacy on | 1 |
failed to improve | 1 |
failed to provide effective disease modification or showed concerning side effects in | 1 |
failed_to_replicate_preclinical | 1 |
failed to show effective disease-modifying outcomes in | 1 |
fails to mediate | 1 |
fails_to_prevent | 1 |
fails to rescue | 1 |
fail to be metabolized to | 1 |
features | 1 |
fits | 1 |
flushes | 1 |
follow distinct stereotypical patterns of progression across | 1 |
follows | 1 |
form | 1 |
form complexes in | 1 |
form in | 1 |
forming | 1 |
forms a mature chaperone complex with | 1 |
forms complexes with | 1 |
forms_complex_in | 1 |
forms nuclear and cytoplasmic inclusions in | 1 |
form the catalytic center of | 1 |
foster | 1 |
found in greatest amounts at | 1 |
functional mediator of | 1 |
function as | 1 |
functions_in | 1 |
fundamentally related to | 1 |
further enhanced in | 1 |
gains capacity to bind | 1 |
genetically correlates with | 1 |
gives rise to consciousness | 1 |
glymphatic_clearance_interacts_with_AB_transport | 1 |
govern | 1 |
governs | 1 |
had good safety without inducing | 1 |
had positive impact on | 1 |
had very little impact on | 1 |
has a critical role in | 1 |
has a crucial role in | 1 |
has a direct role in | 1 |
has a larger effect on | 1 |
has a longer half-life than | 1 |
has a major role in | 1 |
has an inverse correlation with | 1 |
has an oligogenic basis with | 1 |
has a novel role in regulating | 1 |
has a primary role in | 1 |
has a prominent role in | 1 |
has become | 1 |
has been considered as a primary inducing factor of | 1 |
has been correlated with | 1 |
has been found in | 1 |
has been found to continue | 1 |
has been genetically linked to | 1 |
has been gold standard despite | 1 |
has been identified as a | 1 |
has been observed in | 1 |
has been proven to be | 1 |
has been proven to reshape | 1 |
has been regarded as | 1 |
has been shown to play a role in | 1 |
has been shown to promote | 1 |
has been studied in | 1 |
has been the gold standard drug despite | 1 |
has been utilized in | 1 |
has central role in | 1 |
has central roles in | 1 |
has contributed to increased attention on | 1 |
has demonstrated impressive clinical responses in | 1 |
has de novo mutations in | 1 |
has dual | 1 |
has emerged as a means of synchronizing | 1 |
has emerged as an important therapeutic target for | 1 |
has emerged as a potential therapeutic target for | 1 |
has emerged as a promising biomarker for | 1 |
has emerged as a repressor of | 1 |
has emerged as biomarker for | 1 |
has emerged as promising biomarker for | 1 |
has facilitated | 1 |
has functional associations with | 1 |
has implications in | 1 |
has increased association with | 1 |
has initial toxic impact on | 1 |
has kinase-dependent effects on | 1 |
has limited | 1 |
has lower protein levels than | 1 |
has low tau burden but few GABAergic neurons in | 1 |
has modest effect on | 1 |
has mutations in | 1 |
has neuroprotective activity against | 1 |
has neuroprotective effects against | 1 |
has neuroprotective effects through | 1 |
has neuroprotective properties implicated in reducing | 1 |
has no significant interactive effect on | 1 |
has over-representation of | 1 |
has postzygotic mutations in | 1 |
has potential as a therapeutic target to increase | 1 |
has potential as therapeutic target to | 1 |
has potential as therapeutic target to increase | 1 |
has potential for | 1 |
has potential to serve as | 1 |
has potential utility in | 1 |
has protective role associated with | 1 |
has protective role through | 1 |
has_proteomic_landscape | 1 |
has recurrent mutation in | 1 |
has reduced association with | 1 |
has shifted to | 1 |
has shorter fragment length than | 1 |
has specific limitations including | 1 |
has stronger effect size than | 1 |
has strong support for a role in | 1 |
has_subtype | 1 |
has two distinct pathways | 1 |
has unique genetic components separate from | 1 |
has upstream effect on | 1 |
have ability to cross | 1 |
have a non-cell autonomous effect on | 1 |
have a putative role in | 1 |
have a wide range of | 1 |
have been established as genetic risk factors for | 1 |
have been explored for capabilities to protect and restore | 1 |
have been explored for their capabilities to protect and restore | 1 |
have been explored to protect or restore | 1 |
have been identified as significant hallmarks of | 1 |
have been linked to | 1 |
have biologically distinct roles in | 1 |
have biomarker potential for tracking | 1 |
have biomarker value for | 1 |
have deficits in | 1 |
have different | 1 |
have enabled | 1 |
have evolved into | 1 |
have high | 1 |
have interdependent functions in suppressing | 1 |
have large effect on | 1 |
have led to the identification of inhibitors with | 1 |
have modifier effects on | 1 |
have no effect on | 1 |
have positive causal effect on | 1 |
have potential for | 1 |
have reduced incidence and severity of | 1 |
have reduction in | 1 |
have stronger effect on | 1 |
have taken center stage in | 1 |
have two subtypes marked by | 1 |
heightens_vulnerability | 1 |
helps to facilitate | 1 |
helps to restore | 1 |
heralds | 1 |
heterotypically seeds | 1 |
high_affinity_agonist_target | 1 |
highlighted as shared inflammatory | 1 |
highlighted association at gastrointestinal level with | 1 |
highlights novel therapeutic strategies for | 1 |
highly expressed in | 1 |
highly_vulnerable | 1 |
hold promise for the study of | 1 |
hold promise in refining | 1 |
holds promise for | 1 |
homolog_of | 1 |
homologous_to | 1 |
HSP90AA1 modulates tau_propagation | 1 |
human_validation_inconsistent | 1 |
hydrolyzes | 1 |
hyperactive | 1 |
hyperactive_in | 1 |
hypometabolism | 1 |
hypothesized to function as signaling molecule mediating | 1 |
identified | 1 |
identified as | 1 |
identified as most significant | 1 |
identified as most significant pathway affected | 1 |
identified for | 1 |
identified in | 1 |
impact | 1 |
impact on | 1 |
impaired in | 1 |
impaired in some cases of | 1 |
impairs, inhibits, and causes | 1 |
impeded | 1 |
impedes | 1 |
impervious_to | 1 |
implicated as driver of | 1 |
implicated as neural substrate of | 1 |
implicated as selectively vulnerable in | 1 |
implicated in cancer development by enhancing | 1 |
implicated in development of | 1 |
implicated in promoting | 1 |
implicated in the pathways recruiting | 1 |
implications_for | 1 |
implies a potential to contribute to | 1 |
improves and prevents | 1 |
improves depression outcomes by regulating | 1 |
improves_over | 1 |
inactivated | 1 |
included in diagnostic criteria for | 1 |
includes and activates | 1 |
includes strong interactions with | 1 |
increase AD risk by disrupting | 1 |
increased in, indicating activation of | 1 |
increased neuronal vulnerability to | 1 |
increased risk of | 1 |
increased the probability of transition to | 1 |
increased the risk of | 1 |
increase risk for | 1 |
increases_accumulation_of | 1 |
increases AD-related network hyperexcitability | 1 |
increases_before | 1 |
increases_during | 1 |
increases_expression | 1 |
increases_risk_for | 1 |
increases with | 1 |
independently affects | 1 |
independently regulates | 1 |
indicates_AB_clearance_capacity | 1 |
indicates activation of | 1 |
indicates development of | 1 |
indirectly_activated_by | 1 |
indirectly_modulates | 1 |
indirectly_suppresses | 1 |
induce A1 astrocytes by secreting | 1 |
induce autophagic clearance of | 1 |
induced_by | 1 |
induce microglial expression of | 1 |
induces_a1_phenotype | 1 |
induces accumulation of | 1 |
induces and suppresses | 1 |
induces balanced expression of | 1 |
induces balanced expression of by binding to promoters of | 1 |
induces expression of | 1 |
induces_formation | 1 |
induces_misfolding_of | 1 |
induces_oxidative_damage | 1 |
induces_oxidative_stress_in | 1 |
induces reduction of | 1 |
induces secretion of | 1 |
induces senescence in astrocytes via | 1 |
induces spreading of | 1 |
induces_toxicity_in | 1 |
induces transient upregulation followed by decline of | 1 |
induces upregulation of | 1 |
induce the death of | 1 |
ineffective_for | 1 |
ineffective_in | 1 |
infects | 1 |
infiltrated and clonally expanded in | 1 |
inhibited_by | 1 |
inhibited_in | 1 |
inhibited translocation of | 1 |
inhibiting | 1 |
inhibition | 1 |
inhibition_improves | 1 |
inhibits activation of | 1 |
inhibits_formation | 1 |
inhibits postsynaptic functions by attenuating | 1 |
inhibits translocation of STING | 1 |
initially forms in | 1 |
initiates production of | 1 |
innervates | 1 |
interacting with | 1 |
interacts locally in axons with | 1 |
interacts selectively with | 1 |
interacts_with_confidence_0.775 | 1 |
interacts_with_confidence_0.969 | 1 |
interacts_with_confidence_0.99 | 1 |
interacts_with_confidence_0.993 | 1 |
interferes_with | 1 |
internalise membrane via two distinct pathways under physiological electrical stimulation that are | 1 |
internalization | 1 |
interplay to regulate | 1 |
intersects with | 1 |
intertwines with | 1 |
introduces potential therapeutic strategies for | 1 |
invades | 1 |
inversely associated with | 1 |
inversely correlates with | 1 |
involve | 1 |
involved in interplay between | 1 |
is a binding partner of | 1 |
is abundant in | 1 |
is a Ca²⁺-sensing adaptor protein that links | 1 |
is accumulated in | 1 |
is a central player in | 1 |
is a circuit hub in | 1 |
is a commonly used clinical treatment for | 1 |
is a contributing factor in | 1 |
is a critical risk factor for | 1 |
is activatable in | 1 |
is activated in | 1 |
is activated via | 1 |
is a denominator for | 1 |
is a driver of | 1 |
is a functional homologue of | 1 |
is a fundamental driving force in | 1 |
is a future target for | 1 |
is a generalizable strategy for | 1 |
is a hub gene in | 1 |
is a key controlling kinase whose encoding gene is located on | 1 |
is a key modulator of | 1 |
is a key pathway in | 1 |
is a ligand for and triggers | 1 |
is a major component of | 1 |
is a major regulator of | 1 |
is a major triggering factor for | 1 |
is a master regulator for | 1 |
is a master regulator of | 1 |
is a mechanism for | 1 |
is a mechanism of | 1 |
is a molecular link between | 1 |
is among the processes affected by | 1 |
is among the strongest genetic risk factors for | 1 |
is an | 1 |
is an early step in and associated with | 1 |
is an effective therapeutic supplement for halting | 1 |
is an established risk factor for | 1 |
is a network hub and driver in | 1 |
is an important risk factor for | 1 |
is an orally bioavailable precursor of | 1 |
is a novel regulator of | 1 |
is a novel therapeutic target for | 1 |
is a pathological hallmark of | 1 |
is_a_potential_target_for_treating | 1 |
is a potential therapeutic agent for | 1 |
is a potential therapeutic strategy for | 1 |
is a potential therapeutic target for | 1 |
is a principle component of inclusions in | 1 |
is a promising disease-modifying therapy for | 1 |
is a recently approved | 1 |
is a response to | 1 |
is a risk factor associated with | 1 |
is a significant component of | 1 |
is a site of | 1 |
is associated with decline in | 1 |
is associated with delay in | 1 |
is associated with increased risk of | 1 |
is associated with neurodevelopmental disorders whereas HNF1B intragenic mutations are not | 1 |
is a substrate for | 1 |
is a targeted protein degradation technology based on | 1 |
is a top high-risk gene for | 1 |
is attributable to | 1 |
is a type of | 1 |
is a vital form of autophagy for | 1 |
is being compared as biomarker for | 1 |
is beneficial in | 1 |
is biochemically and morphologically essential for promoting | 1 |
is central mediator of | 1 |
is cleared from | 1 |
is closely related to | 1 |
is co-enriched with | 1 |
is compartmentalized within | 1 |
is composed of | 1 |
is considered an important cause of | 1 |
is considered to be a major disease protein in | 1 |
is conveyed by | 1 |
is co-released with | 1 |
is critically involved in | 1 |
is critical prerequisite for | 1 |
is crucial for | 1 |
is defined by | 1 |
is degraded in response to | 1 |
is delayed until | 1 |
is dependent for | 1 |
is dependent on | 1 |
is described as | 1 |
is diffusely distributed in the nucleus and does not localize to | 1 |
is directly involved in | 1 |
is disassembled after | 1 |
is dispensable for | 1 |
is distinguished from | 1 |
is due to (in 2% of cases) | 1 |
is due to (in 98% of cases) | 1 |
is dysregulated in | 1 |
is effective in | 1 |
is efficacious at doses as low as 1 mg/kg given orally once daily in | 1 |
is elevated in | 1 |
is emerging as | 1 |
is engaged in | 1 |
is enriched in | 1 |
is enriched within | 1 |
is expected to be more effective than | 1 |
is expressed | 1 |
is expressed at high levels in | 1 |
is expressed during | 1 |
is expressed only by | 1 |
is expressed primarily in | 1 |
is expressed selectively by | 1 |
is expression of | 1 |
is facilitated by | 1 |
is fundamental to | 1 |
is genetically correlated with | 1 |
is genetically linked to the risk for | 1 |
is heightened in | 1 |
is heterogeneous in | 1 |
is higher in | 1 |
is highest in | 1 |
is highly expressed in neuronal cell bodies of | 1 |
is highly vulnerable to | 1 |
is hypothesized to have a vascular component that may link | 1 |
is identified as partner of | 1 |
is impaired in | 1 |
is impermeable to | 1 |
is implicated as | 1 |
is implicated as neural substrate of | 1 |
is implicated in cancer development by enhancing | 1 |
is implicated in reduced prevalence of | 1 |
is implicated in the pathways recruiting | 1 |
is importantly involved in | 1 |
is important pathogenic mechanism in | 1 |
is imported into | 1 |
is included in | 1 |
is increasingly seen as | 1 |
is integrated into | 1 |
is interconnected with | 1 |
is involved in developing | 1 |
is involved in the assembly of | 1 |
is key regulator of | 1 |
is key to | 1 |
is key to maintaining | 1 |
is less applicable to | 1 |
is less effective than | 1 |
is less evident in | 1 |
is less evident in NHD than | 1 |
is limited by | 1 |
is lineage-specific in | 1 |
is localized in | 1 |
is located on | 1 |
is located within the ER and interacts with ceramide synthase 2 (CERS2) to limit | 1 |
is low in | 1 |
is LRRK2 partner at | 1 |
is marked by | 1 |
is_marker_for | 1 |
is mechanistically and temporally distinct from | 1 |
is mediated via | 1 |
is mediated via suppression of | 1 |
is mediating | 1 |
is metabolized by | 1 |
is modified by | 1 |
is modified by NO resulting in | 1 |
is more directly implicated in the pathophysiology of | 1 |
is more susceptible to | 1 |
is needed as an efficient therapeutic strategy to increase | 1 |
is neither required nor desirable for | 1 |
is not associated with | 1 |
is not expressed by | 1 |
is not strongly associated as | 1 |
is not sufficient to rescue | 1 |
is observed | 1 |
is observed surrounding | 1 |
is often fatal in | 1 |
is one of | 1 |
is one of the hallmarks of | 1 |
is one of the major causative factors to induce | 1 |
is one of the major hallmarks of | 1 |
is one of the pathophysiological mechanisms contributing to | 1 |
is one of the upstream causes of | 1 |
is only modestly enriched in | 1 |
is orchestrated by | 1 |
is overexpressed in | 1 |
is part of | 1 |
is pivotal in | 1 |
is positioned as a critical aging-related gene at the nexus of | 1 |
is_potential_target_for_treating | 1 |
is predictive of | 1 |
is predominantly expressed in | 1 |
is present at | 1 |
is present in close proximity to | 1 |
is primarily provided by | 1 |
is produced in | 1 |
is profoundly affected by | 1 |
is protective against | 1 |
is providing useful information on | 1 |
is recognized as | 1 |
is recognized as a hallmark of | 1 |
is reduced | 1 |
is reflected in | 1 |
is reframed as | 1 |
is regulated at | 1 |
is regulated by | 1 |
is regulated by phosphorylation at | 1 |
is regulated directly by | 1 |
is released through | 1 |
is_reprogrammed_in | 1 |
is required cell autonomously for | 1 |
is required (though not sufficient) for | 1 |
is required, though not sufficient, for | 1 |
is required to limit | 1 |
is robustly induced by | 1 |
is selectively activated in | 1 |
is selectively recruited from the cytosol to | 1 |
is selectively required for | 1 |
is shed by proteases of the ADAM family C-terminal to | 1 |
is significantly more mobile at | 1 |
is significantly upregulated in | 1 |
is specific to | 1 |
is strongly expressed in | 1 |
is sufficient to induce | 1 |
is suggested to be | 1 |
is suggested to be a risk factor for | 1 |
is suppressed in | 1 |
is susceptible to | 1 |
is_synthetic_lethal_with | 1 |
is targeted by therapies in | 1 |
is targeted for | 1 |
is target of | 1 |
is the | 1 |
is the best biomarker for discriminating | 1 |
is the best-characterized inflammasome related to | 1 |
is the central executioner of | 1 |
is the cytopathological hallmark of | 1 |
is the defining pathological hallmark of | 1 |
is the gene responsible for | 1 |
is the hallmark of | 1 |
is the main | 1 |
is the main pathophysiological mechanism for developing | 1 |
is the main risk for | 1 |
is the most informative body fluid for measuring | 1 |
is the most significant risk factor in | 1 |
is the obligate substrate for | 1 |
is the primary determinant of | 1 |
is therapeutic target for | 1 |
is the rate-limiting enzyme of | 1 |
is the rate-limiting step in | 1 |
is the second leading cause of | 1 |
is the second most significant risk factor for | 1 |
is thought to be a critical determinant of | 1 |
is thought to have | 1 |
is tied to | 1 |
is transported to nucleus via | 1 |
is unable to prevent | 1 |
is up-regulated in | 1 |
is upregulated in epilepsy due to downregulation of | 1 |
is upregulated to remove | 1 |
is used as | 1 |
is used to map | 1 |
is_variant_of | 1 |
is vital to | 1 |
is widely recognized as a hallmark of | 1 |
joins | 1 |
joins pantothenate kinase-associated neurodegeneration and PLA2G6-associated neurodegeneration as | 1 |
keeps in check | 1 |
key pathway in | 1 |
kills | 1 |
lacks | 1 |
lactylates | 1 |
leads from | 1 |
leads to accelerated | 1 |
leads to activation of | 1 |
leads to aggregate formation with trapping of | 1 |
leads_to_alterations_in | 1 |
leads to decreased | 1 |
leads to production of | 1 |
leads_to_senescence | 1 |
leaks_across | 1 |
led to decrease in | 1 |
led to reduced | 1 |
less_acidic_in | 1 |
less effective than | 1 |
ligand_for | 1 |
ligates | 1 |
likely explained by | 1 |
limit | 1 |
limited_by | 1 |
limited efficacy due to | 1 |
limited_trafficking_to | 1 |
limits_accumulation | 1 |
limits_formation | 1 |
limits_retention | 1 |
limits treatment efficacy of | 1 |
links DNA damage to | 1 |
links mitochondria to | 1 |
links to | 1 |
loaded_in | 1 |
localization_disruption | 1 |
localized_in | 1 |
localize to | 1 |
located in | 1 |
located primarily in | 1 |
locates_at | 1 |
lose the ability to promote | 1 |
loss_correlates_with | 1 |
loss_linked_to | 1 |
lost during | 1 |
LRP1 modulates tau_propagation | 1 |
lysosomal_trafficking_chaperone | 1 |
maintain | 1 |
maintained | 1 |
maintains balance between | 1 |
maintain the integrity of | 1 |
maintenance | 1 |
manifest in | 1 |
maps to | 1 |
markedly and dose-dependently reduced | 1 |
master_regulator | 1 |
master regulator for | 1 |
matures within and its ectodomain is shed on | 1 |
may aberrantly activate | 1 |
may act as | 1 |
may actually potentiate and augment | 1 |
may alter | 1 |
may be aligned event of | 1 |
may be aligned with | 1 |
may be amplification factor that augments | 1 |
may be a possible novel therapeutic approach for | 1 |
may be a preclinical marker of | 1 |
may be a viable target for | 1 |
may be aware of | 1 |
may be beneficial in | 1 |
may become a new therapeutic target for | 1 |
may be critical for | 1 |
may be linked to | 1 |
may be more cardiotoxic than | 1 |
may benefit | 1 |
may benefit from | 1 |
may be neuroprotective in | 1 |
may be present during | 1 |
may be primarily driven by | 1 |
may be reflection of / involved in | 1 |
may be resistant to | 1 |
may be sensitive biomarkers for | 1 |
may be the initial insult inducing | 1 |
may be useful as | 1 |
may compensate for | 1 |
may confer increased risk for | 1 |
may decrease | 1 |
may disassemble and/or degrade | 1 |
may effectively mitigate | 1 |
may enhance | 1 |
may exhibit | 1 |
may function as | 1 |
may have broader spectrum of | 1 |
may have relevance to | 1 |
may hold therapeutic potentials for treating | 1 |
may include | 1 |
may increase AD risk by disrupting | 1 |
may instruct | 1 |
may involve | 1 |
may lead to an increase in | 1 |
may not involve | 1 |
may play a central role in | 1 |
may play an important role in | 1 |
may preclude | 1 |
may provide | 1 |
may provide a platform for | 1 |
may regulate | 1 |
may represent | 1 |
may represent a potential therapeutic option for | 1 |
may represent a potential therapeutic target for | 1 |
may represent a promising therapeutic target for | 1 |
may represent a successful approach for | 1 |
may represent a suitable treatment for | 1 |
may represent a therapeutic target for | 1 |
may restore | 1 |
may restrict and directly regulate | 1 |
may result in | 1 |
may serve analogous functional roles in | 1 |
may serve as important preclinical contributors to | 1 |
may serve as preclinical contributors to | 1 |
may support prevention and treatment of | 1 |
may trigger | 1 |
measures_global_BBB_permeability | 1 |
mediated approximately 44% of | 1 |
mediated interference in the interaction between | 1 |
mediated the correlation of CSF β2M with | 1 |
mediated the relationship between | 1 |
mediate physiological properties in | 1 |
mediates aberrant synthesis of | 1 |
mediates/accounts for | 1 |
mediates action via | 1 |
mediates anti-inflammatory effects through direct effects on | 1 |
mediates anti-inflammatory role through | 1 |
mediates association of | 1 |
mediates_clearance_of | 1 |
mediates degradation of | 1 |
mediates E2's protective effects against | 1 |
mediates effects through | 1 |
mediates_elimination | 1 |
mediates enhanced slicing of | 1 |
mediates ergogenic effects through | 1 |
mediates_export | 1 |
mediates interference in | 1 |
mediates_loss_of | 1 |
mediates_neuroinflammation_in | 1 |
mediates_phagocytosis | 1 |
mediates proper splicing of | 1 |
mediates_release_of | 1 |
mediates_retrieval_of | 1 |
mediates the effects of | 1 |
mediates the interaction between | 1 |
mediates_ubiquitination | 1 |
mediates ubiquitination degradation of | 1 |
mediates UV-induced proteolysis of | 1 |
mediating | 1 |
melatonin_modulation_target | 1 |
metabolize | 1 |
might be a novel therapeutic target for | 1 |
might be associated with | 1 |
might influence | 1 |
might prevent or delay | 1 |
migrates_to | 1 |
mimics inhibitory effect of sTREM2 on | 1 |
minimizes | 1 |
mirror of | 1 |
misdirects | 1 |
mislocalises from | 1 |
mislocalized | 1 |
mislocalized_to | 1 |
mitigated | 1 |
mitigates_toxicity | 1 |
model features of | 1 |
modified | 1 |
modified_by | 1 |
modifies_infectivity | 1 |
modulates_aggregation | 1 |
modulates attention by regulating | 1 |
modulates_circadian_variations_of | 1 |
modulates_phosphorylation | 1 |
modulates_processing | 1 |
modulates_signaling | 1 |
modulates_via_microglia | 1 |
moved more rapidly through | 1 |
murine_specific_target | 1 |
muscarinic_cross_talk_target | 1 |
must be considered in the context of | 1 |
mutated_in | 1 |
mutation_causes | 1 |
mutations_cause | 1 |
narrow effects | 1 |
necessary and sufficient to induce | 1 |
needed for | 1 |
negatively correlates with | 1 |
negatively correlate with | 1 |
negatively impacts | 1 |
negatively modulates | 1 |
negatively regulate | 1 |
negatively regulated | 1 |
neutralizes | 1 |
NLGN1 modulates tau_propagation | 1 |
no change | 1 |
no evidence of longer-lasting influence on | 1 |
no_GWAS_AD_association | 1 |
nominated proteins implicated in | 1 |
no reduction in | 1 |
normalized | 1 |
normalized at follow up in | 1 |
normalizes_before | 1 |
normalizes_faster_than | 1 |
not_expressed_on | 1 |
not involved in | 1 |
not required for | 1 |
not_required_for | 1 |
observed in both | 1 |
occur in only a subgroup of | 1 |
occurs early in | 1 |
occurs in | 1 |
occurs in genetically predisposed individuals with | 1 |
occurs in regions with | 1 |
occurs in response to | 1 |
occurs via | 1 |
offer as a less invasive alternative to | 1 |
offers mitochondria-targeting strategy for | 1 |
offers potential for | 1 |
offers the potential for | 1 |
offer utility for | 1 |
O-GlcNAcylates | 1 |
operates in a common pathway with | 1 |
operates independent of | 1 |
operates mainly during | 1 |
operates_through | 1 |
opposes | 1 |
opposes rather than directly regulates | 1 |
opsonizes | 1 |
organizes | 1 |
originates_from | 1 |
originates_in | 1 |
oscillate with | 1 |
overabundant_in | 1 |
overcomes | 1 |
overexpression contributes to | 1 |
overexpression_treats | 1 |
paces | 1 |
packages | 1 |
paradoxically increases | 1 |
paralleled by | 1 |
parallels | 1 |
partially_impairs | 1 |
partially rescues | 1 |
partially restored mitochondrial respiration but failed to prevent | 1 |
partially reversed | 1 |
partly reverses | 1 |
PARylates and ubiquitinates | 1 |
pathological_induction | 1 |
pathologically distinguished from | 1 |
pathology_linked_to | 1 |
pathology_target | 1 |
pathway_partner | 1 |
pathway_target_of | 1 |
pathway_upstream_of_BBB_breakdown | 1 |
patrol | 1 |
penetrate | 1 |
penetrated | 1 |
perform | 1 |
performs a pivotal role in directing | 1 |
performs no additional developmental roles besides | 1 |
pericyte_loss_leads_to_neuroaxonal_injury | 1 |
perpetuates | 1 |
persists in | 1 |
phagocytosed_by | 1 |
pharmacological_target | 1 |
phase_advance_target | 1 |
phosphorylated_by | 1 |
phosphorylates and inactivates | 1 |
physically interacts with | 1 |
physically or indirectly interacted with | 1 |
physically or indirectly interacts with | 1 |
platform_for | 1 |
play a contributory role in driving | 1 |
plays a complex anti-inflammatory role that is lost in | 1 |
plays a critical role in induction of | 1 |
plays a critical role in the pathogenesis of | 1 |
plays a critical role in the pathological process of | 1 |
plays a crucial role in | 1 |
plays a crucial role in clearing | 1 |
plays a major role in | 1 |
plays a modest role in | 1 |
plays an essential role in | 1 |
plays an important regulatory role in | 1 |
plays a pivotal role in | 1 |
plays a role in driving | 1 |
plays a role in regulating | 1 |
plays a specific role in | 1 |
plays a structural role in | 1 |
plays a vital role in maintaining | 1 |
plays central role in | 1 |
plays critical role in | 1 |
plays crucial roles in regulating | 1 |
plays important role in | 1 |
plays no role in | 1 |
plays_pivotal_role | 1 |
plays pivotal roles in | 1 |
plays regulatory role in | 1 |
plays role in | 1 |
plays role in progression of | 1 |
plays significant role in | 1 |
plays_vital_role | 1 |
polyubiquitinates | 1 |
: positioned as hub of | 1 |
positioned as molecular gatekeeper linking | 1 |
positions as | 1 |
positive in | 1 |
positively affects | 1 |
positively correlated in CN but attenuated in | 1 |
positively regulates | 1 |
positively_regulates | 1 |
possibly related to | 1 |
post_transcriptionally_upregulates | 1 |
post-translationally_modified_into | 1 |
potential_drug_target | 1 |
potentially plays a role in | 1 |
potential_therapeutic_target | 1 |
preceded | 1 |
precisely control | 1 |
predict | 1 |
predictive for | 1 |
predictors_of | 1 |
predisposes | 1 |
predisposes to | 1 |
predisposes_to | 1 |
predominated in detection rate at | 1 |
predominates in | 1 |
preferentially activated | 1 |
present at | 1 |
presents with | 1 |
preserved in | 1 |
prevalence increases with | 1 |
prevalence in older individuals is | 1 |
prevalence in younger groups is | 1 |
prevalence is | 1 |
prevents_aggregation | 1 |
prevents cognitive impairment through | 1 |
prevents_complete_normalization_of | 1 |
primarily identified in | 1 |
primarily provided by | 1 |
primate-specific feature of | 1 |
primes | 1 |
primes microglia to promote | 1 |
primes microglia to promote tau pathology via | 1 |
prioritizes_over | 1 |
processed_by | 1 |
processes_into_siRNA | 1 |
produce | 1 |
produced by multiple cell types in | 1 |
produces_pathological | 1 |
produces sustained | 1 |
programs | 1 |
progresses preferentially between | 1 |
progressively introduces and accumulates | 1 |
progressively lose sialic acid residues and become primed for | 1 |
prolonged | 1 |
promising approaches to support | 1 |
promote aggregation into | 1 |
promoted: Aryl Hydrocarbon Receptor (AhR) Activation by Microbiome Metabolites Promotes A2 Polarization | 1 |
promoted: Aryl Hydrocarbon Receptor (AHR) Activation in B Cells Determines AQP4 Tolerance Fate | 1 |
promoted: Beta-Hydroxybutyrate Receptor (HCAR2) Signaling Links Ketone Deficiency to Neuroinflammation | 1 |
promoted: C3aR Blockade Disrupts the Microglial-Astrocyte Feedforward Neurotoxic Loop | 1 |
promoted: Complement-SASP Amplification Cascade as Mechanistic Link | 1 |
promoted: Context-Dependent Cx43 Modulation Based on Disease Stage | 1 |
promoted: CSF1R Inhibition-Mediated Microglial Replacement as a State Transition Reset | 1 |
promoted: CSF Biomarker-Guided ABCA7 Therapeutic Dosing | 1 |
promoted: CSF sTREM2 as Pharmacodynamic Biomarker for Therapeutic Window Identification | 1 |
promoted: DAPK1 Inhibition as Dual-Mechanism Neuroprotection Against Tau-Induced Destabilization | 1 |
promoted: DLK MAPK Pathway Inhibition to Block Tau-Induced Neurotoxicity Without Directly Targeting Tau | 1 |
promoted: ER Stress Reduction as Adjunctive Therapy to Support Autophagy | 1 |
promoted formation of | 1 |
promoted: GPC4/HSPGs Collaborate with ApoE Isoforms to Dictate Tau Conformational Strain Uptake Efficiency | 1 |
promoted: H2: Indole-3-Propionate (IPA) as the Actual Neuroprotective Effector | 1 |
promoted: H7: Enteric Nervous System Alpha-Synuclein Propagation Blocker via Gut Barrier Restoration | 1 |
promoted: HDAC6 Selective Inhibition to Restore Acetylation Balance and Microtubule Stability | 1 |
promoted: IL-10-Producing B10 Cells Establish AQP4-Specific Peripheral Tolerance Through Macrophage Reprogramm | 1 |
promoted: IL-6 Trans-Signaling Blockade at the Oligodendrocyte-Microglia Interface | 1 |
promoted: Interneuron SYNGAP1 Deficiency Disrupts Cortical Circuit Assembly During Development | 1 |
promoted: Ketone-Based Metabolic Switching to Restore PV Interneuron Function | 1 |
promoted: M1 Muscarinic Receptor Agonism as Pharmacological Exercise Substitute | 1 |
promoted M1 polarization and inhibited M2 polarization by binding to | 1 |
promoted: MEF2C-Dependent Synaptic Gene Regulation | 1 |
promoted: MFSD2A-Targeted Lysophosphatidylcholine-SPM Conjugates as CNS-Penetrant Pro-Resolving Prodrugs | 1 |
promoted: NAMPT-SIRT1 Axis as Master Regulator of SASP-Dependent Complement Amplification | 1 |
promoted: Optimized Temporal Window for Metabolic Boosting Therapy Determines Success of Microglial State Tran | 1 |
promoted: p38α Inhibitor and PRMT1 Activator Combination to Restore Physiological TDP-43 Phosphorylation-Methy | 1 |
promoted: Parvalbumin Interneuron Vulnerability Links Lactate Transport to Gamma Oscillation Dysfunction | 1 |
promoted: PDE4 Inhibition as Inflammatory Reset for PD Oligodendrocytes | 1 |
promoted: PIKFYVE Inhibition Activates Aggregate Exocytosis via PI(3,5)P2→TRPML1→Calcineurin→TFEB Cascade in A | 1 |
promoted: REDD1-mTOR Axis as the Master Regulator — Preservation Over Chelation | 1 |
promoted: SARM1-Mediated NAD+ Depletion as Terminal Executor of MCT1-Dependent Axon Degeneration | 1 |
promoted: Selective C1q-CRP vs. C1q-IgG Axis Inhibition | 1 |
promoted: Sequential TRPML1 Activation Following Autophagy Priming | 1 |
promoted: SIRT1/PGC-1α Axis Activation to Preserve Mitochondrial Resiliency Against Microbiome-Induced Neuroin | 1 |
promoted: Stathmin-2 Splice Switching to Prevent Axonal Degeneration Across the ALS-FTD-AD Spectrum | 1 |
promoted: STING Antagonism Prevents Acute-to-Chronic Neuroinflammation Transition via Interruption of IFN-I Fe | 1 |
promoted: SUMO1-Mediated Synaptotagmin-1 SUMOylation at Lys124 Impairs Calcium Sensing and Links Synaptic Dysf | 1 |
promoted: SYK-Independent TREM2 Pathways Remain Functional in TYROBP Deficiency | 1 |
promoted: Targeting SASP-Complement Amplification Through HIF-1α Downstream Effectors | 1 |
promoted: TDP-43 Cryptic Exon–Targeted ASOs to Restore Hippocampal Gamma Oscillations | 1 |
promoted: TFEB Nuclear Translocation to Reset Lysosomal-Hypoxia Axis | 1 |
promoted: Timed Senolytic Therapy Eliminates p16^Ink4a/p21^Cip1-Senescent Microglia to Prevent SASP-Driven Com | 1 |
promoted: TLR4/MyD88/NF-κB Axis Blockade to Interrupt LPS-Mediated Gut-Brain Neuroinflammation in PD | 1 |
promoted: TREM2 Agonism to Restore Microglial Phagocytosis Across Both Pathologies | 1 |
promoted: TREM2 R47H Metabolic Lock-in at Cholesterol Ester Accumulation | 1 |
promoted: TRPML1-PINK1/Parkin Axis Coordinates Mitophagy with Lysosomal Biogenesis | 1 |
promotes_apoptosis | 1 |
promotes_autophagic_degradation | 1 |
promotes_autophagic_degradation_of | 1 |
promotes autophagy-lysosome degradation of | 1 |
promotes clearance of | 1 |
promotes death of | 1 |
promotes degradation of | 1 |
promotes_degradation_of | 1 |
promotes efficient elimination of | 1 |
promotes_escape | 1 |
promotes_ferroptosis | 1 |
promotes fibrillation of | 1 |
promotes greater expression of | 1 |
promotes healthy ageing through regulation of | 1 |
promotes M1 polarization of microglia following SCI by upregulating | 1 |
promotes maintenance of | 1 |
promotes mitophagy via | 1 |
promotes_nuclear_import_of | 1 |
promotes_nuclear_translocation | 1 |
promotes nuclear translocation of | 1 |
promotes_recruitment | 1 |
promotes release of | 1 |
promotes_SUMOylation_of | 1 |
promotes the formation of | 1 |
propagate from | 1 |
propagates_along | 1 |
propagates from | 1 |
propagates from neuron to neuron in | 1 |
propagates_through | 1 |
propagates via | 1 |
propagates_via | 1 |
propagating from | 1 |
propagation_route_for | 1 |
proposed as possible early biomarkers of | 1 |
proposed to play a role in flushing | 1 |
proposes a deterministic chain of events leading from | 1 |
protect | 1 |
protect and restore | 1 |
protect during systemic circulation | 1 |
protected_against | 1 |
protective_effect | 1 |
protects against AD through | 1 |
protects and inhibits ferroptosis in | 1 |
protects cells from | 1 |
protects from | 1 |
protects retinal neurons from | 1 |
provide | 1 |
provide a window to examine | 1 |
provide clues to | 1 |
provided by | 1 |
provides a platform for | 1 |
provides explanation for | 1 |
provides for encoding | 1 |
provides rationale for | 1 |
provides_relevant_surrogate | 1 |
provides significant benefit to overcome | 1 |
provides_system_to_study | 1 |
prunes | 1 |
rarely manifests in | 1 |
rarely present in | 1 |
rate_limits | 1 |
recapitulates | 1 |
receives inputs from | 1 |
receive synaptic input from | 1 |
receptor_desensitization_regulators | 1 |
receptor_for | 1 |
recognized_by | 1 |
recognizes and sorts | 1 |
recognizes_for_ER_targeting | 1 |
recognizes resulting in assembly and activation of | 1 |
recovered | 1 |
recruited to | 1 |
recruits_and_activates | 1 |
recruits FOXG1 to | 1 |
recruits_Hsc70_clients_to | 1 |
recruits JIP4 to lysosomes in a kinase-dependent manner via phosphorylation of | 1 |
recruits JIP4 to lysosomes via phosphorylation of | 1 |
recruits_to_mitochondria | 1 |
recruits_to_TGN | 1 |
redirected_to | 1 |
redirects | 1 |
redistributes to | 1 |
redistributes to cytoplasm where it co-aggregates with | 1 |
reduced_activity_in | 1 |
reduced decline in | 1 |
reduced in | 1 |
reduced_in | 1 |
reduced latency to | 1 |
reduced_levels_in | 1 |
reduced via | 1 |
reduces and decreases | 1 |
reduces endogenous | 1 |
reduces glucose utilization and promotes | 1 |
reduces inhibitory tone to | 1 |
reduces_phosphorylation_of | 1 |
reduces_risk_of | 1 |
refers to | 1 |
reflects_pericyte_coverage | 1 |
reflects_recovery_of | 1 |
regulate BBB integrity through | 1 |
regulate in a tissue-specific manner | 1 |
regulate release of | 1 |
regulates_alternative_splicing | 1 |
regulates Ca2+ influx into photoreceptor cells by activating | 1 |
regulates ceramide levels by mediating stability of | 1 |
regulates cholesterol and lipid metabolism in | 1 |
regulates GPX4/HO-1 by alleviating lipid peroxidation induced by suppression of | 1 |
regulates in a neuron-specific manner | 1 |
regulates microglial activity including | 1 |
regulates mitochondrial dynamics through | 1 |
regulates mitochondrial dynamics via | 1 |
regulates mRNA metabolism by interacting with | 1 |
regulates_pathway_in | 1 |
regulates_propagation | 1 |
regulates_retrograde_signaling_of | 1 |
regulates SG assembly via | 1 |
regulates_splicing_of | 1 |
regulates_stability_by_targeting_FBXL7 | 1 |
regulates target genes within | 1 |
regulates, thereby impinging upon | 1 |
regulates transcription of | 1 |
regulates transformation of | 1 |
regulates_translation | 1 |
regulating | 1 |
reinvigorate | 1 |
relatively_spared | 1 |
release | 1 |
released_from | 1 |
released_in | 1 |
release functional mitochondria that enter | 1 |
relieves | 1 |
remain intact in the face of | 1 |
remains | 1 |
remains permeable to | 1 |
remain the core biological hallmark of | 1 |
removes_ubiquitin_from | 1 |
renders Akt a valuable | 1 |
renders impermeable | 1 |
renders_resistant_to | 1 |
reorganizes with | 1 |
repairs intestinal barrier by inhibiting | 1 |
replace | 1 |
reports_endothelial_activation | 1 |
represent a fundamental neurophysiological unit supporting | 1 |
represented | 1 |
represent potential targets for | 1 |
represents a potential | 1 |
represents potential for | 1 |
represents target for | 1 |
repressed_by | 1 |
represses expression of | 1 |
represses_translation | 1 |
require efficient transport to | 1 |
requires conserved residues within for Golgi recruitment and kinase activation | 1 |
requires_for_lipidation | 1 |
requires_for_nuclear_export | 1 |
requires optimization for | 1 |
rescue | 1 |
rescues and stimulates | 1 |
rescues neurons from ischemic insult via | 1 |
resemble | 1 |
resembles neuroinflammation process governed by | 1 |
resets | 1 |
reside on | 1 |
resides in but aberrantly processes to form cytoplasmic inclusions in | 1 |
responds to and initiates assembly through | 1 |
respond to diffuse white light stimulation with | 1 |
responsible for eliminating | 1 |
restores dopaminergic function by suppressing | 1 |
restores_voltage_gating | 1 |
restrains | 1 |
restricted to | 1 |
resulted in reduction of | 1 |
resulting in | 1 |
results from | 1 |
results in activation of | 1 |
results in an increase in | 1 |
return towards pre-randomization levels more quickly than | 1 |
revealed | 1 |
revealed hierarchical organization from | 1 |
revealed in | 1 |
revolutionized treatment of | 1 |
risk_gene_for | 1 |
role in pathogenesis of | 1 |
screens | 1 |
secrete | 1 |
secreted | 1 |
secreted from | 1 |
seeds | 1 |
segregates | 1 |
segregates from | 1 |
segregates partially from | 1 |
selected for in | 1 |
selectively accumulates in | 1 |
selectively augmented | 1 |
selectively causes degeneration in | 1 |
selectively lowered | 1 |
selectively reduce | 1 |
selectively_tags | 1 |
selectively_vulnerable | 1 |
sequester and promote phase separation of | 1 |
sequestered in | 1 |
sequestered_in | 1 |
sequestered inside | 1 |
serves as epigenetic regulator in terms of | 1 |
serves as substrate for | 1 |
severed_by | 1 |
shapes_into_pro-inflammatory_phenotype | 1 |
share | 1 |
share a common etiology involving | 1 |
share characteristics in common with | 1 |
share common pathological feature of | 1 |
share common structural features typical for | 1 |
share conserved amino acid sequence and/or structure with | 1 |
shares converging intracellular signaling pathway with | 1 |
shares differentially expressed genes with | 1 |
share significant genetic correlation with | 1 |
share significant genetic overlap with | 1 |
shares overlapping features with | 1 |
shares pathogenetic mechanisms with | 1 |
shares_theme | 1 |
shed from | 1 |
shift | 1 |
shifted from | 1 |
shifts tryptophan metabolism from | 1 |
shorten | 1 |
shortens_and_shapes | 1 |
should be defined using | 1 |
should be reserved for | 1 |
show decline | 1 |
show defect in | 1 |
show differential abundance across | 1 |
show differential abundance in | 1 |
show differential accessibility in | 1 |
show early response to | 1 |
showed association at brain level with | 1 |
showed association in cross-tissue analysis with | 1 |
showed characteristic organization with | 1 |
showed differences in | 1 |
showed dose-dependent improvement in | 1 |
showed enrichment with | 1 |
showed expansion of | 1 |
showed high discrimination power between | 1 |
showed in | 1 |
showed increased association with | 1 |
showed lack of | 1 |
showed long-lasting improvements in | 1 |
showed no association with | 1 |
showed no changes following | 1 |
showed no indication of | 1 |
showed no significant interaction effect on | 1 |
showed positive impact on | 1 |
showed significant signal enrichment in | 1 |
showed stress-induced upregulation of | 1 |
showed stronger cross-species conservation than in | 1 |
showed the best performance among | 1 |
show enrichment for | 1 |
show heightened steady-state activation of | 1 |
show hierarchical organization of | 1 |
show increased infiltration and expression of | 1 |
show no evidence of | 1 |
show no indication of | 1 |
shows decreased interaction with | 1 |
shows elevated phosphorylation at | 1 |
shows enrichment with | 1 |
shows equivocal association with | 1 |
shows genome-wide significant | 1 |
shows higher longitudinal increases than | 1 |
shows less availability for | 1 |
shows major correlative association with | 1 |
shows more dispersion along | 1 |
show specialization between | 1 |
show specific enrichments of | 1 |
shows potential as | 1 |
shows protection against | 1 |
shows quantitative differences in | 1 |
shows resistance due to | 1 |
shows significant enrichment for | 1 |
shows similar attenuation as | 1 |
show strong linear relationship across | 1 |
shows virtually no abnormal inclusions within | 1 |
show upregulation of | 1 |
show utility in | 1 |
show vulnerability and myelin alterations | 1 |
shuttle | 1 |
signaling_dysregulated_in | 1 |
signaling molecule mediating | 1 |
signaling_requires | 1 |
signals_via | 1 |
significantly altered | 1 |
significantly delayed | 1 |
significantly elevated in | 1 |
significantly slowed | 1 |
sits at the interface between | 1 |
slow | 1 |
SNAP25 modulates tau_propagation | 1 |
spans a spectrum of | 1 |
specifically phosphorylates | 1 |
specifically reduced | 1 |
specifically regulates | 1 |
specifically targets | 1 |
specifying | 1 |
spreads_along | 1 |
spreads and worsens with time, taking over more regions | 1 |
spreads in | 1 |
spreads_to | 1 |
spreads_via | 1 |
start to increase at very early stages of | 1 |
stimulate directly | 1 |
stimulates_differentiation | 1 |
stimulates mitochondrial respiration via | 1 |
stimulates stability of | 1 |
stimulates SYK activation more potently than | 1 |
strengthened with | 1 |
strongly binds to | 1 |
strongly increases the risk of developing | 1 |
substrate_for | 1 |
successful in controlling | 1 |
successfully mitigates | 1 |
suggested to be | 1 |
suggested to be associated with | 1 |
suggests | 1 |
SUMOylates | 1 |
SUMOylation | 1 |
support | 1 |
support biological coherence of | 1 |
supports utility as potential | 1 |
suppressed and induced | 1 |
suppressed_by_high_dose_melatonin | 1 |
suppressed while sparing | 1 |
suppresses and induces | 1 |
suppresses_transcription | 1 |
suppression_associated_with | 1 |
susceptible_to | 1 |
sustained_activation_in_AD | 1 |
synapse_loss_linked_to | 1 |
synaptic output onto | 1 |
synchronizes | 1 |
synergistically_mediates | 1 |
synergistic_with | 1 |
synergize to drive | 1 |
synthetic_lethal_with | 1 |
tag and are consequently removed by | 1 |
taken_up_by | 1 |
take up | 1 |
targeted | 1 |
targeted and negatively regulated | 1 |
Target ESCRT-III complex components (CHMP4B, VPS4) to selectively reduce tau-containing extracellula | 1 |
target_for_age_adjusted_replacement | 1 |
targets and negatively regulates | 1 |
Target SNAP25 interactions to prevent tau uptake at presynaptic terminals during vesicle recycling. | 1 |
target_validation_failed | 1 |
T_cell_recruitment | 1 |
terminate directly in | 1 |
therapeutic_for | 1 |
therapeutic_reduction_of_extends_lifespan_and_reduces_pathology | 1 |
therapeutic_target_of | 1 |
toxic_to | 1 |
traffics | 1 |
traffics_across | 1 |
transactivation_is_crucial_for | 1 |
transcribe | 1 |
transcriptional_activation | 1 |
transcriptional_activator_of | 1 |
transcriptional_complex | 1 |
transcriptional_regulation | 1 |
transduce | 1 |
transduce and communicate via | 1 |
transfer mitochondria to | 1 |
transfers_via_TNT | 1 |
transiently_rescues | 1 |
transitions into | 1 |
translocated to | 1 |
translocates to and promotes removal of | 1 |
transmits | 1 |
transmits extracellular signals from | 1 |
transmits information about | 1 |
transmits information about protein folding status to | 1 |
transmits signals for | 1 |
transmits signals involved in | 1 |
transported from | 1 |
transport_via_transcytosis | 1 |
travel to and aggravate | 1 |
TREM2 modulates tau_propagation | 1 |
trended toward an inverse relationship with | 1 |
triggered | 1 |
triggered by | 1 |
trigger multicellular response that ultimately leads to | 1 |
triggers_dysfunction | 1 |
triggers SASP via activation of | 1 |
triggers_ubiquitination_dependent_degradation_by_TRIM25 | 1 |
triggers_via_CD18 | 1 |
typically show a negative correlation with | 1 |
ubiquitinated_by | 1 |
ubiquitin-mediated degradation | 1 |
undergo a developmental switch from | 1 |
undergoes glutathionylation of | 1 |
undergoes incorporation into | 1 |
underlie | 1 |
underlie_sensitivity_to | 1 |
underlies_sensitivity_to | 1 |
underlying pathophysiological mechanisms | 1 |
underscores important role for | 1 |
universally presents with | 1 |
upregulate | 1 |
upregulated HMGB1 expression by sponging | 1 |
up-regulated or down-regulated in | 1 |
upregulates expression of through | 1 |
upregulates_in_DAM | 1 |
upstream_driver | 1 |
used for treatment of | 1 |
used_to_treat | 1 |
uses_neurotransmitter | 1 |
uses signaling pathways to ameliorate | 1 |
uses to convert | 1 |
valid as | 1 |
varies by | 1 |
vary in their ability to clear | 1 |
VCP modulates tau_propagation | 1 |
vulnerability_for | 1 |
vulnerability_locus_for | 1 |
vulnerable_in | 1 |
was activated in | 1 |
was associated with | 1 |
was associated with reduced | 1 |
was attenuated by | 1 |
was common in | 1 |
was delayed until | 1 |
was dependent on | 1 |
was elevated | 1 |
was elevated in | 1 |
was found | 1 |
was greatest in | 1 |
was highly expressed in | 1 |
was highly increased in | 1 |
was identified as | 1 |
was increased by | 1 |
was increased in microglia near | 1 |
was inversely associated with | 1 |
was investigated as | 1 |
was largely devoid of | 1 |
was largely restricted to | 1 |
was located in | 1 |
was negatively correlated with | 1 |
was not associated with increased risk of | 1 |
was not associated with significant | 1 |
was not associated with significant change in | 1 |
was not correlated with | 1 |
was not detected | 1 |
was not responsive to | 1 |
was only | 1 |
was positively correlated with | 1 |
was proven to be safe and well tolerated in | 1 |
was reduced in | 1 |
was reduced in early stages and highly increased in | 1 |
was safe and well-tolerated in | 1 |
was significantly associated with higher levels of | 1 |
was significantly correlated to | 1 |
was strongly activated in | 1 |
was the best predictor of | 1 |
was the highest among | 1 |
was unlikely to meet | 1 |
was upregulated and localized to | 1 |
was up-regulated in | 1 |
weakened binding to | 1 |
weakened in | 1 |
weakly_related_to | 1 |
were almost undetectable in | 1 |
were available to mice for | 1 |
were categorized and listed as | 1 |
were correlated with | 1 |
were detected in | 1 |
were higher along the septo-temporal axis in the septal direction | 1 |
were identified as potential targets of | 1 |
were increased in | 1 |
were largely | 1 |
were neuroprotective against | 1 |
were overactivated, releasing abundant | 1 |
were present at significantly higher frequency in | 1 |
were reduced in relation to | 1 |
were significantly higher in | 1 |
were strong predictors of | 1 |
were task-related (changed firing rate) | 1 |
widespread in | 1 |
will be measured in individuals with FRDA using | 1 |
would facilitate transformation to | 1 |